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A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2008 
 
Major Director:  H. THOMAS KARNES, Ph.D. 
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Each year in the U.S., approximately 7-8 million patients with non-traumatic chest 
pain visit hospital emergency departments (ED) for medical evaluation.  It is estimated that 
approximately 2-5% of these patients are experiencing acute cardiac ischemia, but due to 
the shortcomings of current test methods, they are incorrectly diagnosed and discharged 
without appropriate treatment provided, thus leading to poor patient outcome and potential 
medical malpractice litigation.  The goals of this research were to evaluate plasma samples 
 xxvi
for potential biomarker(s) of acute cardiac ischemia prior to heart tissue necrosis, and to 
ultimately develop a rapid method for detection of the potential biomarker(s) in human 
plasma.  Initial experiments were performed using the mouse model, with subsequent 
evaluations on human plasma samples using high performance liquid chromatographic 
ultraviolet detection (HPLC-UV).  The final phase of this research involved the 
development of a rapid luminometer test method (<10 min analysis time objective) to be 
potentially used in the clinical laboratory environment. 
 An HPLC-UV detection method was developed and utilized for inosine, 
hypoxanthine and other adenosine triphosphate (ATP) catabolic by-products in Krebs-
Henseleit (Krebs) buffer solution, with analysis on perfusate samples from isolated mouse 
hearts undergoing 20 min acute global ischemia.  The HPLC-UV method was modified for 
subsequent use on human plasma samples, obtained from hospital emergency department 
(ED) patients presenting with non-traumatic chest pain (potential acute cardiac ischemia) 
and from healthy normal individuals.  The HPLC-UV (component quantification) and 
HPLC-MS (component identification) test methods utilized C18 column technology, 
mobile phases consisting of aqueous trifluoroacetic acid (0.05% TFA in deionized water 
pH 2.2, v/v) and methanol gradient to achieve component separation, with both utilizing 
simple sample preparations (e.g. direct injection of Krebs perfusate samples and 
centrifugal membrane filtration on plasma samples). 
 Results of the animal experiments using isolated mouse hearts undergoing 20 min 
acute global ischemia demonstrated significant levels of endogenous inosine effluxed from 
the heart tissue, indicating its use as a potential candidate biomarker of acute cardiac 
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ischemia.  The HPLC results from human plasma representing ED non-traumatic chest 
pain patients demonstrated elevated levels of inosine (hypoxanthine precursor) and 
significant levels of hypoxanthine, which provided additional support for the use of these 
candidate biomarker(s) as a potential diagnostic tool for the initial acute cardiac ischemic 
event, prior to heart tissue necrosis. 
 The final phase of this research focused on the development of a rapid, simple and 
sensitive chemiluminescence test method.  Using a microplate luminometer with direct 
injectors and continuous mixing, the measurement of inosine and hypoxanthine in human 
plasma was achieved for healthy normal individuals and on patients with confirmed acute 
MI, with an analysis time of less than 5 minutes.  The utility of this rapid luminescence 
technique would be the potential use at point-of-care (POC) services (e.g. hospital clinical 
laboratory or emergency medical services) as part of the initial ED treatment protocol on 
patients presenting with non-traumatic chest pain and signs/symptoms of acute myocardial 
ischemia or acute MI. 
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CHAPTER 1. Background and Significance 
 
1.1 Introduction and Request for Additional Biomarkers 
Cardiovascular diseases (e.g. acute myocardial infarction (MI)) are the leading 
cause of mortality in the world [Naudziunas et al., 2005; Okrainec et al., 2004; Dorner et 
al., 2004, AHRQ, 2000].  Each year in the US, approximately 7-8 million patients present 
with non-traumatic chest pain and seek emergency medical treatment [Morrow et al., 
2007].  Current emergency medical evaluation on these patients suspected of having acute 
MI includes obtaining patient history, signs and symptoms, vitals, electrocardiogram 
(ECG) and blood evaluation for specific cardiac biomarkers [Beyerle, 2002; A.D.A.M. 
Inc., 2005; Lees, 2000].  However, the percent diagnostic accuracy of acute MI when using 
patient signs and symptoms, ECG and c-troponin is only approximately 50%.  With the 
addition of the recently FDA cleared albumin cobalt binding assay, the diagnostic accuracy 
improves to approximately 70%; hence the need for additional research for biomarkers of 
acute cardiac ischemia to further improve patient diagnostic accuracy is important. 
The hospital emergency department blood evaluation determines levels of several 
specific endogenous cardiac protein biomarkers (e.g. cardiac troponin I and T (cTnI, 
cTnT), creatine kinase-MB (CK-MB) isoform, and myoglobin).  However, these protein 
biomarkers are indicative of cardiac tissue necrosis, and are typically detected hours after 
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the acute cardiac event (infarct), and not at the time of acute cardiac ischemia, which may 
include angina (stable or unstable, but non-necrotic). 
One recent published scientific editorial requested the need for early onset 
biomarkers of acute cardiac ischemia prior to cardiac tissue necrosis [Morrow et al., 2003].  
Ideally, these early onset biomarkers would aid emergency medical services (EMS) 
personnel in the rapid diagnosis and treatment of initial acute cardiac ischemia (potentially 
acute MI), thus increasing the survival rate of acute MI victims every year.  One research 
group [Bhagavan et al., 2003] addressing the scientific editorial request, describes a blood 
measurement for ischemia modified albumin (IMA), which appears at an elevated level in 
the bloodstream from patients undergoing an ischemic cardiac event; however the author’s 
state that the colorimetric test would not discriminate between cardiac ischemic patients 
with and without acute MI (e.g. angina), and recent clinical evaluations of the test assay 
have reported significant false positive results. 
Table 1 depicts the US and world wide heart attack (HA) statistics compiled in 
2002 and clearly demonstrates the critical need for additional endogenous biomarkers of 
early onset cardiac ischemia [World Health Organization (WHO), 2002].  As can be seen 
from the WHO heart attack statistics table, approximately 24 individuals die every minute 
in the world from heart attacks, with many individuals waiting more than two hours before 
seeking medical attention.  The American Heart Association cites that approximately 75-
80% of the heart attacks occur at home, with up to 95% dying before ever reaching a 
hospital [American Heart Association Statistics, 2007].  Thus, the need for continued 
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Table 1.  World Health Organization (WHO) 2002 Heart Attack Statistics. 
Heart Attack (HA) Statistics (WHO 2002)
~1.1 million US heart 
attacks each year 
~32 million worldwide heart 
attacks each year 
• ~650,000 HA are first events 
• ~450,000 HA are recurrences
• ~511,000 HA are fatal each year
• ~47% HA victims die every day or
• ~1,400 HA victims die every day or
• ~58 HA victims die every hour or
• ~1 HA victim dies every minute
• ~50% HA victims wait >2 hrs. before
getting help
• ~40 - 75% die before reaching the hospital
• ~12.5 million HA are fatal each year
Worldwide statistics US statistics 
~24 HA victims die every minute
Heart Attack (HA) Statistics (WHO 2002) 
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additional research for additional biomarkers of acute cardiac ischemia is critical in 
addressing the health care community requests [Maisel et al., 2005, Morrow et al., 2007, 
Apple et al., 2005]. 
1.2 Biomarkers, Use and Requirements 
Biomarker is a term defined by the U.S. Food and Drug Administration (FDA) as 
“a characteristic that is objectively measured and evaluated as an indicator of normal 
biologic or pathogenic processes or pharmacological responses to a therapeutic 
intervention.” [FDA, Rockville, USA].  Examples of current biomarkers in human blood 
that are commonly used to aid in diagnosis and treatment of medical conditions are 
hemoglobin-A1c and glucose levels for diabetes, cardiac protein troponin I (cTnI) and 
creatine-kinase MB (CK-MB) isoenzyme (both being very specific to cardiac tissue) for 
acute MI, and hormone human chorionic gonadotropin (hCG) for pregnancy testing 
[Bloom et al., 2003]. 
A biomarker is classified as a surrogate endpoint, which is an objective 
characteristic, intended to substitute for a clinical (and sometimes subjective) endpoint 
[Biomarker World Congress 2007, USA].  For example, one clinical endpoint for acute MI 
can be how the person feels (e.g. chest pain, nausea, fatigue), which can be subjective and 
caused by other various medical conditions (Table 2).  However, using current biomarker 
surrogate endpoints for acute MI (elevated plasma concentrations of cardiac proteins 
myoglobin, CK-MB and cTnI or cTnT) significantly improves patient diagnostic accuracy, 
and may led to prompter emergency medical intervention (treatments), and improved 
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Table 2.  Listing of various medical conditions causing non-traumatic chest pain other than 
acute cardiac ischemia and acute MI.  Information tabulated from Prehospital Emergency 
Care, 7th Edition, Mistovich et al., 2004. 
Condition Symptom profile 
Gastroesophageal reflux Dull to sharp chest pain, chest pressure, nausea and vomiting 
Acid Reflux Dull chest pain, chest pressure, heartburn 
Angina Breathlessness or choking feeling, heavy weight or tightening 
across the upper chest 
Musculoskeletal Sharp pains confined to a specific area of the chest 
Pneumonia Sharp pain on side of the chest, anxiety, rapid breathing 
Aortic Dissection Ripping or tearing pain, shortness of breath, abdominal pain, 
fainting 
Nerve Impingement Shooting, burning pain, numbness 
Pulmonary Embolus Shortness of breath, rapid breathing and sharp pain in the mid 
chest 
Spontaneous Pneumothorax Shortness of breath, sharp chest pain, rapid heart rate, 
dizziness 
Acute Pericarditis Sharp or stabbing pain in the mid chest 
Heartburn Burning pain in chest, nausea, vomiting 
Asthma Shortness of breath, wheezing or cough 
Anxiety Palpitations, sweating, muscle tension, fatigue 
Peptic Ulcer Abdominal pain below the sternum, nausea, vomiting 
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patient outcomes.  A “routine biomarker” is currently defined as the use of FDA approved 
commercial kits and assays for testing in diagnostic labs (e.g. cTnI and CK-MB are routine 
biomarkers used as indicators of acute MI).  A “novel biomarker” is currently defined as a 
non-routine kit or assay “for research only,” and typically utilized in biotechnology 
(discovery) or academic environments [Biomarker World Congress 2007, USA]. 
An example of how one recent novel biomarker progressed into a routine 
biomarker is the current use of ischemia modified albumin as an indicator for acute cardiac 
ischemia.  A detailed description of this test will be later described in Section 1.4.  Many 
years of research (>10 years) went into the development of using ischemia modified 
albumin as a potential biomarker of acute cardiac ischemia, with the first US patent being 
filed in 1991 [Bar-Or et al, 1991], and subsequent FDA clearance for use 12 years later in 
2003 (assay was initially called albumin cobalt binding (ACB) and is currently called 
ischemia modified albumin (IMA)). 
 Some considerations are important in the discovery and development of a potential 
endogenous plasma biomarker.  If the biomarker is endogenous to plasma, it may exhibit 
circadian fluctuations in basal concentrations levels.  For example, C-reactive protein 
(CRP), which is currently recognized as an endogenous plasma biomarker of 
inflammation, has both seasonal and diurnal variation in a patient’s basal plasma 
concentration.  Thusly, if measuring CRP, it would have been important to document the 
date and time of the blood sample draw, as it may have affected the diagnostic 
interpretation of the laboratory sample results. 
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Several other important biomarker considerations are determining (or sourcing 
from reported literature) the half-life and whether co-existing medical conditions (e.g. 
kidney disease) affects the plasma biomarker concentrations.  Knowing the component 
half-life is important as some plasma biomarkers have very short half-lives (e.g. inosine is 
less than 5 minutes), while others may have longer half-lives (e.g. cTnI can be detected for 
several days).  It is well documented that patients diagnosed with chronic renal failure 
typically have high plasma levels of many constituents due to their kidney clearance 
problems.  Thus the need for their frequent hemodialysis treatments, and potential errors in 
interpreting their plasma test results.  Typically, plasma biomarker discoveries involve the 
use of techniques such as LC-MS, with subsequent clinical use of the FDA cleared 
biomarker typically employing automated clinical platforms utilizing immunoassay or 
enzymatic techniques [Biomarker World Congress, 2007]. 
Use of endogenous plasma biomarkers as medical diagnostic tools is a relatively 
new field in industry, as compared to discovery and development of drugs (pharmaceutical 
industry); however both industries are regulated by the US FDA.  One important difference 
between these two regulated industries is that when using endogenous plasma biomarkers 
as a diagnostic tool, it is important to demonstrate the proof-of-concept (proof-of-biology) 
on how the level of the biomarker relates to the associated disease condition.  Approval of 
pharmaceutical drugs typically requires clinical studies demonstrating patient safety and 
efficacy evaluations; however the exact biological mechanism-of-action is not always 
known (e.g. some cancer drugs are known to be efficacious, without fully understanding 
the exact mechanism of action). 
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For medical diagnostic biomarkers, it is important to link the biomarker with the 
disease condition and patient clinical outcome.  This requires either published scientific 
knowledge or demonstration of the mechanism-of-action on how the endogenous plasma 
biomarker change is associated with the disease condition.  For example, the human 
plasma level of cTnI is normally found at <0.05 µg/L in healthy normal individuals, but 
under conditions of acute cardiac MI, the levels of cTnI are significantly elevated (≥0.05 
µg/L) due to the affected heart tissue (necrotic) being diffused into the bloodstream, which 
causes the increase in the concentration of cardiac troponins (e.g. cTnI, cTnT).  Chapter 2 
of this research utilizes the mouse model to demonstrate the proof-of-concept (proof-of-
biology) that one ATP catabolic by-product, inosine, may be a potential candidate 
biomarker of acute global cardiac ischemia. 
Current requirements for proposed biomarker test methods to address are 
component specificity and sensitivity.  Specificity is a term defined as the uniqueness of 
the biomarker for the disease or condition for which it will be used to aid in patient 
diagnosis.  Specificity is the test procedure’s ability to measure a negative response 
(minimize false positives).  Conversely, sensitivity is a term defined as the ability of a test 
procedure to measure a positive response.  For many analytical measurements, sensitivity 
is directly related to the method detection limit and slope of the detector response relative 
to the concentration level of the analyte (e.g. low method detection limit and large positive 
slope typically indicates a sensitive test method).  The test method detection limit is an 
important parameter to determine and is defined as the ratio of analyte signal to matrix and 
instrument electronic noise.  The goal of a good biomarker test method is to possess both a 
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high specificity (reduce the number of false positive results) and high sensitivity (reduce 
the number of false negative results).  Insufficient evaluation of these criteria may lead to 
poor patient outcomes (e.g. false positives may lead to erroneous medical treatment(s) and 
psychological stress and false negatives may lead to poor patient prognosis, especially for 
cancer patients). 
As the field of medical diagnostics and use of biomarkers continues to grow, it is 
important to standardize the method development approach and validation requirements of 
biomarker assays.  In recent years, representatives from pharmaceutical, biotechnology, 
and medical diagnostic companies have jointly collaborated, and drafted initial guidelines 
to be used for biomarker method development and validation, covering both qualitative 
and quantitative assays [Lee et al., 2006].  Conferences such as the Biomarker World 
Congress have several meetings annually with attending representatives (domestic and 
international) from industry, biotechnology, academia, and government (e.g. FDA). 
Biomarker discovery and development success rate to the market place (i.e. clinical 
laboratory or point-of-care) is very similar to the pharmaceutical industry, with just a 
fraction of the discovered biomarkers being successfully utilized in the clinical laboratory.  
Although there has been approximately 4,000 biomarkers reported in the literature, less 
than 100 have been cleared for use by the FDA, and less than 10 are routinely used in the 
clinics [Biomarker World Congress, 2007].  Of the endogenous biomarkers that are 
currently being used, concentration level changes in plasma are all less than 10-fold 
increases, with most biomarkers having less than a 5-fold increase in concentration level 
[Biomarker World Congress, 2007].  As will be reported in Chapter 4 of this dissertation, 
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our proposed candidate biomarker(s) inosine and hypoxanthine from hospital room 
emergency room patients exhibiting non-traumatic chest pain; had plasma concentrations 
(called total hypoxanthine as inosine is converted to hypoxanthine using purine nucleoside 
phosphorylase enzyme) above the 5-fold increase typically found in the currently used 
FDA cleared biomarkers. 
1.3 Biomarkers of Acute Myocardial Infarction 
The biomarkers that are currently used for detection of acute MI are myoglobin, 
CK-MB and either cTnI or cTnT.  These are biomarkers of cardiac tissue necrosis and can 
be used individually, but more emphasis has been placed on using panels of these cardiac 
biomarkers together (e.g. simultaneous evaluation of myoglobin, CK-MB and cTnI).  The 
rationale for using a cardiac panel of biomarkers is that it improves the diagnostic 
accuracy, as ultimately more information is gathered to use for patient diagnosis.  There 
has been other cardiac biomarkers of acute MI over the years, many being replaced as new 
discoveries find better biomarkers demonstrating higher specificity and sensitivity (e.g. 
lactate dehydrogenase replaced by current acute MI biomarkers). 
As can be seen in Table 3 (Cortez Diagnostics, CA, USA) and Figure 1, the cardiac 
biomarkers have completely different onset and duration profiles (leading to different half-
lives).  Myoglobin (MW ~17 kDa) is found in muscle tissue and transports cellular oxygen 
consumed by muscle mitochondria.  Although it is a very sensitive biomarker of muscle 
tissue necrosis, it is not totally specific to heart tissue and can also be found in other 
muscle tissue (e.g. skeletal).  In a medical situation consisting of an ischemic event 
involving both cardiac and skeletal muscle, elevated levels of myoglobin may be present 
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Table 3.  Cardiac tissue necrosis biomarker detection time after AMI onset, normal 
individual plasma range, and the biomarker duration time (Information from Cardiac Panel 
Test Strip Information Sheet, Cortez Diagnostics, CA, USA). 
 
    Test Strip
Detection time Normal Remain cut-off
Marker after onset of AMI range elevated level 
     Myo 1-4 hrs 30 - 90 ng/ml < 12 hrs 70 ng/ml 
CK-MB 4-6 hrs < 5 ng/ml ~24 hrs 5 ng/ml 
cTnI 10-12 hrs ND 60-80 hrs 1 ng/ml 
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Figure 1.  Serum profile of plasma biomarkers (myoglobin, CK-MB, troponins, and lactate 
dehydrogenase (LD)) representing human cardiac tissue necrosis.  Profile depicts differing 
onset and duration of cardiac biomarkers after an acute MI event.  Picture with permission 
from Futura Publishing Company, Inc., NY, USA. 
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from either form of muscle, thus leading to potential confounding results if only using 
myoglobin as the cardiac biomarker. 
Instead, many clinical labs utilize multiple cardiac biomarkers (currently called 
cardiac panels) to improve patient diagnosis (increases predictive value).  CK-MB (MW ~ 
41 kDa) is an isoenzyme of the creatine kinase (CK) family of enzymes and is primarily 
found in heart muscle tissue.  Although it is more specific to heart muscle tissue than 
myoglobin, it can not be detected until approximately 4-6 hours after the acute MI event.  
The latest cardiac biomarkers to be utilized are the cardiac troponins (cTnI, MW 24 kDa 
and cTnT, MW 34 kDa).  These biomarkers are highly specific to cardiac muscle tissue, 
but like CK-MB, are not readily detected until 4-8 hours after the acute MI event.  The 
high specificity of the troponin proteins can be explained as both are structural components 
of the thin filament of cardiac muscle tissue; hence necrosis of the affected cardiac tissue 
followed by the body’s elimination of the necrotic tissue into the bloodstream, would cause 
a significant elevation of these biomarkers (which neither is normally found at detectable 
levels in the bloodstream with the currently used immunoassay techniques). 
1.4 Biomarkers of Acute Myocardial Ischemia 
There are several plasma biomarkers currently under evaluation for acute 
myocardial ischemia; however only one to date has been cleared for use by the FDA.  The 
current biomarker assays are ischemia modified albumin (IMA), unbound free fatty acids 
(FFAu) and choline [Apple et al., 2005].  Of the three, only IMA has received FDA 
clearance (2003) for marketing as a diagnostic cardiac biomarker.  It is worthwhile to 
briefly discuss each of these candidate biomarkers as to their proof of biology (if known) 
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and why they appear elevated in the bloodstream under conditions of acute cardiac 
ischemia. 
Choline (HOCH2CH2N+(CH3)3) is one major product formed from the 
phosphodiesteric cleavage of membrane phospholipid phosphatidylcholine.  During an 
ischemic event, phospholipase D (PLD) is activated and cleaves membrane 
phosphatidylcholine into phosphatidic acid and choline, which is subsequently released 
into the blood stream and can be detected.  Evaluation of choline was made using LC-MS 
technology.  At the time of the review article describing its potential use as a biomarker, it 
was recommended that the development of rapid point-of-care and central laboratory assay 
were still needed to further evaluate this biomarker’s usefulness [Apple et al, 2005].  This 
recommendation is not surprising as most clinical laboratories utilize commercially bought 
kit assays, which are typically immunological techniques (e.g. enzyme linked 
immunosorbent assay (ELISA)). 
Ischemia modified albumin (IMA) is the term given to serum albumin that has been 
modified by the reaction with free radicals generated by heart tissue undergoing acute 
cardiac ischemic conditions.  The premise of this biomarker candidate is that free radials 
(e.g. hydroxyl) generated by ischemic heart tissue can react with albumin in the 
bloodstream forming a “modified albumin”, which can be subsequently detected using a 
colorimetric technique.  The exact mechanism is still unclear, but it is hypothesized that 
free radicals attach irreversibly to the amino end terminus of the albumin protein, creating 
a modified albumin moiety.  Briefly, the assay utilizes an aqueous cobalt chloride solution, 
with cobalt typically able to bind to the amino terminus of serum albumin (which normally 
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binds and transports transition metals like cobalt).  However, under conditions of acute 
cardiac ischemia and the formation of the modified albumin moiety, the cobalt can not 
bind to the n-terminus of albumin, and the resulting solution will have an intense blue 
color (as cobalt will instead bind with the test reagent dithiothreitol); which is measurable 
using a spectrophotometer.  A spectrometer can be found used in a routine chemistry 
analyzer typically found in clinical laboratories. 
Several IMA method conditions are important to list: the avoidance of sample 
collection using chelators (e.g. EDTA) as it would interfere with the analysis by binding to 
divalent cations (e.g. calcium, cobalt, magnesium), and to analyze the sample within 2.5 
hrs of the blood draw (unless stored frozen at -20°C).  Currently, there are clinical 
chemistry platforms for this analysis with on-going investigations on the potential use of 
immunoassay techniques.  Although this biomarker has been cleared by the FDA for use, 
several clinical studies have reported the test to have significant false positive results (e.g. 
increased IMA values may be found in patients with cancer, liver disease, brain ischemia, 
end-stage renal disease, and infections [Apple et al., 2005; Asian D. et al., 2005; Wu, 
2003]) and the analysis cost is fairly high (2006 US Medicaid reimbursement cost was 
~$47 per test).  As the diagnostic predictive accuracy of using IMA results alone is <50% 
[Sinha et al, 2003, Bagavan et al., 2003], it is important to mention that the FDA clearance 
of the IMA test was based on its use in conjunction with two other acute MI diagnostic 
tests (e.g. electrocardiogram (ECG) and cardiac troponin (e.g. cTnI)), which significantly 
increased the overall patient diagnostic accuracy. 
 43
Free fatty acids (FFA) are typically found in serum bound to albumin with a small 
amount typically found in the unbound form (FFAu, free).  However, under conditions of 
cardiac ischemia, the levels of FFAu are found elevated, with the exact understanding of 
why (mechanism-of-action) the FFAu is found elevated remaining unclear.  The FFAu 
analysis consists of the binding the unbound FFA to a protein labeled with a fluorescent 
tag, and subsequent measurement using a fluorometer.  It was recommended that 
additional clinical evaluations were necessary to further evaluate this candidate biomarker 
[Apple et al., 2005]. 
1.5 Past Research on Inosine and Hypoxanthine 
Inosine and hypoxanthine are found in human plasma at low basal concentrations 
(inosine 0.75-1.49 µM, hypoxanthine 1.47-2.94 µM) normally resulting from purine 
metabolism [Feng et al., 2000].  Past research has been performed evaluating inosine and 
hypoxanthine in humans to explore their possible roles in response to ischemia and to also 
determine what role inosine may have as an immunosuppressant.  Several research groups 
have published articles evaluating nucleotide breakdown products in blood during 
ischemic cardiac events (e.g. pacing induced angina, acute MI) and utilized HPLC test 
methods for analysis. 
For example, one group studied the role of xanthine oxidase in purine metabolism 
in ischemic humans [Kock et al., 2003].  They evaluated components such as 
hypoxanthine, xanthine and uric acid, but these authors did not measure inosine and 
reported insignificant differences in hypoxanthine concentrations (mean [µM], SD) 
between normal male individuals (11.9 µM, 4.1), and patients with MI (16.2 µM, 7.1) and 
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other ischemic diseases (e.g. angina pectoris, 11.9 µM, 5.0).  Our research in Chapter 4 
(Section 4.4) focused on addressing the differences in hypoxanthine results from our 
experiments using plasma (lithium heparin) and Kock’s group; which used serum with gel 
(SST) for their experiments. 
Another group studied normal volunteers and patients with documented ischemic 
heart disease; utilized an atrial pacing stress test and reported elevated levels of 
hypoxanthine using HPLC, but insignificant levels of adenosine, inosine and xanthine 
[Harmsen et al., 1981].  While these authors evaluated cardiac ischemic patients and found 
hypoxanthine concentrations to be elevated, they also reported insignificant levels of 
inosine (hypoxanthine precursor); which our Chapter 4 research reports significant 
concentrations of both hypoxanthine and inosine from our study patients.  The differences 
in inosine results may be explained by differences in the cardiac patient types.  Harmsen’s 
group used ischemic heart disease patients and performed the atrial pacing stress test, 
which may end after a brief period of time (e.g. 20-30 min).  This is somewhat different 
than what our cardiac patient samples represent; which were all from a local hospital 
emergency department’s group of non-traumatic chest pain patients.  These patients, which 
may have potential acute cardiac ischemia, had reported non-traumatic chest pain that may 
have been occurring for many hours (e.g. 2 to >10 hrs.), thus allowing concentrations of 
the ATP catabolic by-products (e.g. inosine, hypoxanthine) to elevate in the blood stream. 
Toguzov’s group reported a rise in purine metabolic end products in patients with 
angina and MI [Toguzov et al., 1989].  Their overall conclusion was that plasma 
concentrations of xanthine and uric acid were better indicators of the severity of cardiac 
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ischemia than were inosine and hypoxanthine.  Since xanthine and uric acid can both be 
elevated by other patient medical conditions (e.g. elevated xanthine with xanthine oxidase 
deficiency and elevated levels of uric acid with gout); these two substances may have false 
positives associated with their use as potential cardiac biomarkers. 
Although other research groups have worked with patients with cardiac disease 
(e.g. ischemia, acute MI, angina), there have been no reported studies on nucleotide 
catabolic by-products in plasma from patients (hospital emergency department) presenting 
with non-traumatic chest pain and potential acute cardiac ischemia, nor have any groups 
published a simple, rapid and sensitive test method (goal of <10 min and for clinical 
laboratory) for nucleotide catabolic components inosine and hypoxanthine in plasma. 
Animal research in the area of cardiac ischemia has also been performed with 
publications demonstrating inosine and hypoxanthine cardiac efflux utilizing experiments 
with animal models such as the dog and pig [Jennings et al., 1981; Backstrom et al., 2003], 
with one group using the mouse model and adenosine metabolism inhibitors to study the 
mechanism underlying inosine cardio protection [Peart et al., 2001].  Jennings et al. used 
the dog (healthy mongrel) model for their experiments.  In brief, these investigators 
performed in-vitro (excised heart) and in-vivo experiments, inducing ischemia and then 
evaluating the eluted nucleotides and their by-products (e.g. inosine, hypoxanthine).  They 
concluded that when inducing cardiac ischemia on in-vitro (total ischemia) and in-vivo 
(severe ischemia) heart tissue, that elevated levels of inosine and hypoxanthine were 
detected (after 15 min for in-vivo, after 60 min for in-vitro).  Peart et al. used isolated 
mouse hearts to evaluate adenosine metabolism inhibitors during periods of cardiac 
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ischemia.  Their conclusion was that adenosine deaminase and kinase inhibition (via 
enzyme inhibitors) provided cardioprotection (from reducing the xanthine/xanthine oxidase 
reaction and the generation of damaging free radicals).  Although their research goal 
(enzyme inhibitor evaluations using wild type C57/BL6 and transgenic mice) was 
somewhat different than our animal model research goal (cardiac ischemia marker proof of 
concept using ICR heterogeneous mice), both groups used isolated mouse hearts for the 
experiments.  To meet the goal of cardiac ischemia marker proof of concept, the isolated 
mouse heart tissue represented less potential confounding results (e.g. clean matrix from 
Krebs perfusate and removal of body compensations to ischemia) plus the mouse is easy to 
use and relatively inexpensive to purchase/maintain. 
Backstrom et al. used the pig model for their experiments, with microdialysis 
catheterization at several different blood vessel sites (e.g. great cardiac vein, pulmonary 
artery), and then used arterial occlusion to induce cardiac ischemia for various times (0, 10, 
15 and 60 min).  They reported significant dialysate concentrations of inosine and 
hypoxanthine at ischemic time points of 15 and 60 min relative to baseline concentrations 
(ischemic time point 0 min), and concluded that there was a graded outflow of amino acids 
and purines in response to ischemic conditions. 
1.6 Research Hypothesis and Significance 
The research hypothesis is that during periods of acute cardiac ischemia in patients 
presenting with non-traumatic chest pain (hospital emergency department), plasma 
concentrations of inosine (hypoxanthine precursor) and hypoxanthine would be 
significantly elevated above their normally low endogenous plasma concentrations, and 
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potentially becoming candidate biomarkers indicative of the pre-necrotic acute cardiac 
ischemic event.  As acute cardiac ischemia is an event prior to potential acute myocardial 
infarction, the affected heart tissue in the ischemic area is still functional and not yet 
necrotic, as are tissue from an acute myocardial infarction (AMI). 
The current biomarkers indicative of AMI are relatively large protein components 
(e.g. myoglobin, CK-MB, and troponins with each larger than 10,000 Da) which are 
released from necrotic heart tissue.  However, inosine and hypoxanthine; which are ATP 
catabolic by-products and small polar substances (MW inosine 268 Da, MW hypoxanthine 
136 Da), are transported by passive diffusion from affected heart tissue into the 
bloodstream.  Since an acute cardiac ischemic event occurs prior to potential AMI, it is 
hypothesized that the concentrations of inosine and hypoxanthine should appear elevated 
in the bloodstream prior to elevated concentrations of protein biomarkers indicative of 
AMI (which are detected several hours after the AMI event). 
The significance of this research would be the identification of potential candidate 
biomarker(s) of acute cardiac ischemia and the development of a rapid analysis (<10 min) 
to use for the biomarker measurement.  Ideally, EMS personnel would benefit from this 
biomarker and rapid test method to guide in their diagnostic and treatment steps for non-
traumatic chest pain patients, as there are more than ten medical conditions other than 
acute MI that may cause non-traumatic chest pain (e.g. anxiety attack, acid reflux, angina).  
However, one limitation of using elevated concentrations of inosine and hypoxanthine as a 
biomarker of acute cardiac ischemia is these biomarkers may not differentiate a patient 
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experiencing acute cardiac ischemia prior to AMI, or experiencing cardiac angina without 
AMI. 
1.7 Overall Research Experimental Design 
The research is divided into three study phases, with each study phase being 
completed prior to beginning the next (i.e. each subsequent study phase builds from the 
prior study phase).  The study phases are briefly described below with a general outline of 
all three phases listed afterwards. 
Phase I (Chapter 2) study has the overall goal of comparing control and ischemic 
isolated mouse hearts to identify potential biomarkers of acute cardiac ischemia.  HPLC 
methodologies (DAD and MS detection) will be developed and used for all sample 
analysis from Phase I experiments.  As aspirin (ASA) is currently used for human patients 
suspected of undergoing acute myocardial infarction (a condition that may occur after an 
acute cardiac ischemic event), it will be investigated (Chapter 3).  Since aspirin is rapidly 
metabolized to salicylic acid (SA) in the body; SA will be investigated and used for the 
additional isolated mouse heart experiments undergoing ischemic conditions.  The goal is 
to determine the effect of SA on the biomarkers from Chapter 2 experiments. 
Phase II (Chapter 4) study has the goal of evaluating blood samples to determine if 
the biomarker identified in Chapter 2 is present in human plasma and then measure the 
concentrations.  HPLC methodology (UV detection) will be used for all sample analysis in 
Phase II studies.  IRB approval will be obtained for the use of blood samples represented 
healthy normal individuals and non-traumatic chest pain patients (from a local hospital 
emergency department).  Additional experiments will be performed using different types of 
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sample collection additives (e.g. serum separator tube (SST), matched sets of heparin 
plasma and SST).  The goal is to determine if the SST additive (e.g. gel) causes potential 
artifacts in biomarker concentration and state the preferred blood sample collection 
additive for any future work on the potential biomarkers. 
Phase III (Chapter 5) study has the overall goal of developing a rapid and simple 
screening assay (i.e. potential diagnostic tool) to use in a clinical environment.  A 
microplate luminometer will be purchased, setup and utilized for plasma (lithium heparin) 
analysis.  Evaluations of enzyme (e.g. xanthine oxidase, purine nucleoside phosphorylase) 
concentration and incubation times will be performed to optimize assay conditions and 
achieve a rapid analysis time.  The screening assay will be tested on plasma from healthy 
normal individuals and cardiac patients with acute myocardial infarction (as defined by 
elevated levels of cardiac troponin I).  The goal is to determine if potential biomarker 
concentrations are significantly different between these two groups (normal subjects versus 
acute MI patients). 
Each of the three phases of studies can also be listed as follows: 
Phase I - Animal studies to identify potential biomarkers of acute cardiac ischemia 
and demonstrate biomarker proof-of-concept 
• Evaluate potential biomarker(s) from animal model (isolated mouse hearts) 
undergoing 20 min acute global cardiac ischemic conditions.  Evaluate test (ischemic) and 
control animal perfusate samples (n=6 each group) using HPLC methodology. 
• Evaluate effects of salicylic acid (aspirin metabolite) in Krebs buffer solution on 
the potential biomarker(s) levels, as aspirin (platelet inhibitor) is currently used for initial 
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treatment on patients presenting with non-traumatic chest pain and potential acute 
myocardial infarction. 
• Develop quantitative HPLC-DAD (diode array detection) test method for 
evaluation of Krebs perfusate samples from the animal experiments.  Utilize LC-MS 
method for biomarker component identification. 
• Calculate total biomarker efflux (area under the curve, AUC) and utilize statistics 
(e.g. t-test, ANOVA) for data analysis on control and test group results. 
Phase II - Human plasma evaluation for identified biomarker(s) from Phase I studies 
• Obtain human plasma samples (n=20 each group) from emergency department 
(ED) non-traumatic chest pain patients and healthy individuals (controls, non-symptomatic 
for acute cardiac ischemia) following institutional review board (IRB) and hospital 
departmental approvals. 
• Develop and validate HPLC-UV method for quantitative evaluation of inosine and 
hypoxanthine in human plasma. 
• Statistically evaluate HPLC plasma results using parametric techniques (e.g. t-test) 
using α=0.05 with p<0.05 demonstrating statistical significance between test and control 
group plasma samples. 
• Evaluate effects of sample collection matrix (e.g. lithium heparin plasma, serum 
separator tube) on levels of inosine and hypoxanthine from human samples. 
Phase III – Develop rapid test method for biomarker(s) from Phase II studies 
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• Develop a rapid, simple, and sensitive plasma luminescence test method (<10 min 
analysis time) for potential use by emergency medical services (EMS) or clinical lab 
environment. 
• Evaluate plasma samples (n=6 each) from healthy individuals and hospital acute 
MI patients (hospital documented elevated cTnT levels).  Compare results statistically 
using t-test and using a calculated biomarker cut-off limit (e.g. 99th percentile). 
 52
 
CHAPTER 2. Animal Studies to Demonstrate Proof-of-Concept, “HPLC 
Determination of Inosine, a Potential Biomarker for Initial Cardiac 
Ischemia using Isolated Mouse Hearts” 
 
 
2.1 Introduction 
 
In this chapter of research, animal studies were performed to identify potential 
biomarker(s) of acute cardiac ischemia and to demonstrate the potential biomarker(s) 
proof-of-concept (via mechanism of action).  The rationale of using isolated mouse hearts 
for these experiments was to eliminate potential confounding factors (e.g. body 
metabolism, body compensatory mechanisms) that may occur with in-vivo type 
experiments.  Ischemia is defined as a reduced blood flow and results in reduced oxygen 
supply to the affected site (tissue).  As a consequence to the lack of oxygen in heart muscle 
tissue, adenosine triphosphate (ATP) production in the cardiac cell’s mitochondria would 
be limited to anaerobic production. 
Thus, it is important to understand how the heart utilizes ATP, a high energy 
phosphate molecule, to perform its circulatory function.  The heart is highly energy-
dependent on ATP, which is made in cardiac cellular mitochondria by either aerobic 
(oxidative phosphorylation via electron transport chain) or anaerobic (glycolysis) 
processes.  The aerobic process is heavily oxygen dependent and generates approximately 
80% of cardiac cellular ATP.  The anaerobic process is independent of oxygen and 
produces approximately 20% of the cardiac cellular ATP; with lactic acid as a by-product. 
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For production of large quantities of ATP, human cardiac cells have an abundance 
of mitochondria which comprise approximately 40-50% of the cardiac cellular mass.  
When cardiac tissue is subjected to periods of constant oxidative stress (e.g. cardiac 
ischemia), insufficient oxygen is available for cardiac mitochondria to aerobically 
synthesize the ATP required for normal cardiac function.  This causes a cellular 
accumulation of ATP metabolic by-products (e.g. adenosine diphosphate (ADP), 
adenosine monophosphate (AMP)) and activates normally dormant enzymes (e.g. 5´-
nucleotidase, adenosine deaminase, purine nucleoside phosphorylase and xanthine oxidase) 
to catabolize the ATP by-products to substances such as adenosine, inosine, hypoxanthine, 
xanthine and uric acid for cardiac cellular elimination [Abd-Elfattah et al., 2001].  In 
human cardiac tissue, another source of ATP metabolic by-products is through metabolism 
of diadenosine polyphosphates, which are released from cardiac-specific secretory granules 
during periods of cardiac metabolic or ischemic stress to provide cellular protective 
functions [Luo et al., 2004]. 
Inosine (9-β-D-ribofuranosylhypoxanthine) is an endogenous purine nucleoside 
normally found in the human body as a degradation component of purine metabolism.  In 
human plasma, inosine is metabolized in red blood cells with a reported half-life of <5 min 
with endogenous plasma levels found in trace amounts (e.g. low ng/mL) [Viegas et.al., 
2000].  In humans, nature has provided a cellular biochemical mechanism to help conserve 
energy in producing the required large quantities of ATP for cardiac cellular use (called 
salvage pathway), which can convert cellular inosine back to ATP via several enzymatic 
steps; thus recycling cellular inosine [Nelson et al., 2000].  However, in periods of constant 
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cardiac oxidative stress (e.g. 20 min), cardiac cells buildup significant amounts of ATP 
metabolic by-products, which activate normally dormant enzymes to catabolize ATP by-
products, which then become systemically available prior to their elimination. 
The research hypothesis is that prior to extra-cellular biomarkers (e.g. free radical 
modified serum albumin) appearing in the bloodstream from cardiac ischemic events, 
plasma inosine levels should be elevated above normally low endogenous levels, thus 
becoming a useful biomarker of pre-necrotic acute cardiac ischemia.  Adenosine, another 
nucleoside metabolic by-product of ATP catabolism is metabolized by red blood cells and 
has a very short plasma half-life (e.g. ~15 sec); thus making it more difficult to 
quantitatively measure in plasma [Mei et.al., 1996].  The three other metabolic by-products 
(xanthine, hypoxanthine and uric acid) are normally found at higher levels in the plasma, 
but would lack the necessary specificity due to potential contributions from other human 
disease state conditions (e.g. plasma uric acid levels elevated in gout; plasma xanthine 
levels elevated in xanthine oxidase deficient individuals). 
The ICR (Institute of Cancer Research) outbred mouse [Dohm, 2004] was used as 
the animal model for all isolated heart experiments and utilized a Langendorff apparatus 
[Xi et al., 1998].  For sample analysis, a developed analytical method utilized a high 
performance liquid chromatographic diode array detection (HPLC-DAD) for the detection 
and quantification of inosine in Krebs-Henseleit (Krebs) buffer solution.  A Synergy C18 
column (hydrophobic/hydrophilic reversed phased retention) at a flow rate of 0.6 ml/min 
with an aqueous mobile phase of trifluoroacetic acid (0.05% TFA in deionized water pH 
2.2, v/v) and methanol gradient was used for component separation.  The assay detection 
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limit for inosine in Krebs buffer solution was 500 ng/mL using a 100 μL neat injection.  
The HPLC results were used to determine total cardiac effluxed inosine (AUC) into the 
Krebs effluent for each mouse during acute global cardiac ischemia (oxidative stress) and 
compared to percent cardiac ventricular functional recovery to determine if a relationship 
exists amongst this cardiovascular parameter during periods of acute global cardiac 
ischemia. 
2.2 Experimental 
2.2.1 Chemicals, Mobile Phase and Krebs Buffer Solution 
 Hypoxanthine and xanthine were purchased from Acros Organics (Fair Lawn, NJ, 
USA). 2,3-dihydroxybenzoic acid (DHBA), 2,5-dihydroxybenzoic acid, salicylic acid 
(SA), adensosine, inosine and uric acid were purchased from Sigma-Aldrich (St. Louis, 
MO, USA).  Sodium chloride, sodium bicarbonate, potassium chloride, magnesium sulfate, 
monobasic potassium dihydrogen phosphate, dextrose and calcium chloride were used to 
prepare the Krebs buffer solution and all were purchased from Sigma-Aldrich.  All 
purchased chemicals were ACS reagent grade or better.  The Krebs buffer solution [118.5 
mM NaCl, 25.0 mM NaHCO3, 11.1 mM C6H6O6, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM 
MgSO4 and 2.5 mM CaCl2] was prepared in ultrapure deionized water with pH 7.4 and 
95%O2:5%CO2.  For mobile phase preparation, trifluoroacetic acid (TFA) was reagent 
grade and methanol was Optima HPLC grade and both were purchased from Fisher 
Scientific (Fair Lawn, NJ, USA).  Ultrapure distilled and deionized water (18 MΩ-cm) 
used for HPLC work was prepared in-house using Purelab Ultra deionized water system 
(US Filter, Lowell, MA, USA) and filtered prior to use. 
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2.2.2 Preparation of Standard Solutions 
 Stock standards of 93.6 µM adenosine, 93.2 µM inosine, 183.7 µM hypoxanthine, 
164.4 µM xanthine and 148.7 µM uric acid were prepared in deionized water and stored at 
4°C.  Working standards (1:10 dilution of stock standard) of each component were 
prepared in Krebs buffer solution and maintained at -20°C along with the mouse Krebs 
buffer eluant samples.  The working standards stored at -20°C were stable for at least 6 
months. 
2.2.3 HPLC-UV and HPLC-MS Equipment Set Points 
 
For inosine quantification and diode array spectral purity, the HPLC equipment 
consisted of Agilent Model 1100 Quaternary HPLC-DAD and Chemstation software (Palo 
Alto, CA, USA).  The DAD was set to acquire complete UV spectrum for component 
specificity with 240 nm used for quantification of inosine and the other ATP metabolic by-
products.  For inosine confirmation, LC/MS was used and the equipment consisted of a 
Shimadzu LCMS-2010A HPLC coupled to a single quadrapole mass spectrometer using 
LCMS Solutions software (Columbia, MD, USA).  The HPLC-MS conditions consisted of 
using ESI with the following instrument set points (heating block at 300°C, nebulizer at 4 
L/min nitrogen, interface voltage at 2 kV) and full scan acquisition using positive ion 
mode. 
The analytical column for both HPLC-DAD and HPLC-MS analysis was a 
Synergi™ Hydro-RP C18, 150 mm x 3 mm I.D., 4 μm packing, 80 Å (Phenomenex®, 
Torrance, CA, USA).  The C18 guard column was a 30 mm x 4.6 mm I.D., 40-50 μm 
pellicular packing (Alltech, Deerfield, IL, USA).  The mobile phase consisted of aqueous 
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trifluoroacetic acid (0.05% TFA in deionized water, v/v, and pH 2.2) and methanol 
gradient.  The mobile phase gradient was linear with time course as follows (95:5 0.05% 
TFA in deionized water: methanol, v/v at 0 min; 70:30 0.05% TFA in deionized water: 
methanol, v/v at 12 min; 10:90 0.05% TFA in deionized water: methanol, v/v at 13 min 
and held 3 min, and 95:5 0.05% TFA in deionized water: methanol, v/v at 17 min). 
The mobile phase was degassed automatically using an Agilent 1100 membrane 
degasser with a flow-rate of 0.6 ml/min.  An injection volume of 100 μl of the Krebs buffer 
eluant was made using an autosampler.  Typical HPLC operating pressure was 
approximately 150 bar with ambient column oven temperature and 345 kPa back-pressure 
regulator (SSI, State College, PA, USA) to prevent mobile phase outgassing in the 
detector. 
2.2.4 ICR Mouse Experiment Conditions 
ICR mice were used for all isolated mouse heart experiments with morphometric 
characteristics and baseline cardiac function of the adult mice (ICR strain) provided in 
Table 4.  The mice were anaesthetized; hearts surgically removed and isolated using the 
Langendorff apparatus (Figure 2).  Global cardiac oxidative stress was accomplished by 
adjusting the Krebs buffered solution to zero flow through the heart for 20 min.  Upon 
heart reperfusion, approximately 1.5 mL samples of Krebs buffered eluant from the 
isolated mouse hearts were collected at predetermined time-points (0, 1, 3, 5, 10 and 20 
min) in plastic bullet centrifuge tubes and frozen at -20°C until HPLC-DAD analysis. 
 To evaluate the effects of oxidative stress on the mouse heart, established 
cardiovascular measurements (e.g. ventricular functional recovery) were performed on 
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Table 4. Morphometric characteristics and baseline cardiac function of the adult mice (ICR 
strain). 
________________________________________________________________________ 
     Control  Ischemia-Reperfusion Test 
          (n = 6)              (n = 6) 
________________________________________________________________________ 
 
Body Weight (g)   42.2 ± 1.3   38.7 ± 2.1 
Heart Wet Weight (mg)   258 ± 6    242 ± 14 
Heart Rate (bpm)    368 ± 23    345 ± 23 
Developed Force (g)   0.81 ± 0.19   1.12 ± 0.12 
Rate-Force Product (g x bpm)  308 ± 80    372 ± 49 
Coronary Flow (ml/min)    2.3 ± 0.2     1.7 ± 0.1 
________________________________________________________________________ 
 
Values are mean ± SEM.  No significant difference (P>0.05) between the groups was 
found for the listed parameters, except coronary flow. 
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Figure 2. Modified Landendorff apparatus used for all animal (mouse) experiments.  The 
suspended isolated heart has Krebs buffer solution perfusing through it to provide 
sufficient nutrients (e.g. buffer salts, glucose, oxygen etc.) for experiments. 
Experiments Using
Modified Langendorff Apparatus 
Air temperature 
measurement 
Krebs buffer
(constant temp)
Syringe pump 
for admin drugs
Heart tensioner
device
Suspended
mouse heart,
viable for
several hours.
Courtesy of Dr. Lei Xi, VCU Cardiology
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both control (non-ischemic conditions) and test (ischemic conditions) animals (n=6 for 
each group).  Our methodology for evaluating the isolated perfused mouse heart has been 
previously described [Xi et al., 1998]. In brief, animals are anesthetized with an 
intraperitoneal injection of pentobarbital sodium ([100 mg/kg] with 33 IU heparin added).  
The heart was removed and immediately placed in ice-cold Krebs buffer.  The aorta was 
cannulated within 3 min onto the Langendorff perfusion system and the heart was perfused 
in a retrograde fashion at a constant pressure of 55 mmHg with Krebs buffer gassed with 
95%O2 and 5%CO2.  The pH of the buffer and the heart temperature were maintained at 
7.35-7.50 and 37±0.5ºC, respectively.  A force-displacement transducer (Grass, FT03) was 
attached to the apex via a metal hook/surgical thread/pulley system to continuously record 
and measure ventricular contractile force and heart rate.  For each heart the resting tension 
was set at ~0.3 g in the beginning of the experiment. 
The protocol for the test group consisted of 30 min of stabilization, 20 min of zero-
flow global ischemia, and 30 min of reperfusion [Xi et al., 1998].  Time-matched normoxic 
perfusion was carried out for the control group.  At the end of each experiment, the heart 
was removed from the Langendorff system, quickly weighed and stored at -20°C. 
2.2.5 Sample Preparation, Stability, and Instrument Precision Evaluation 
 Prior to HPLC analysis, perfusate samples frozen at -20°C were thawed to ambient 
temperature, mixed thoroughly by inversion and transferred to plastic autosampler vials for 
subsequent direct injection into the HPLC-DAD system.  To evaluate sample stability in 
the perfusate solution and instrument precision; prepared samples in autosampler vials 
 61
were stored at ambient lab temperature overnight and re-injected (n=3 times) into the 
HPLC for analysis. 
2.2.6 Component Retention Times, Inosine Calibration and AUC Calculations 
 During HPLC method development and validation, standards of adenosine (3.7 to 
93.6 µM), inosine (3.7 to 93.2 µM), hypoxanthine (7.3 to 183.7 µM), xanthine (6.6 to 
164.4 µM) and uric acid (5.9 to 148.7 µM) were prepared in Krebs buffer solution.  
Standard curve linearity (non-weighted) of all components was acceptable with all 
correlation coefficients >0.995.  During subsequent analytical runs, a single point 
calibration standard mixture (9.3 µM inosine, 18.4 µM hypoxanthine, 9.4 µM adenosine, 
16.4 µM xanthine and 14.9 µM uric acid) was prepared in Krebs buffer solution and was 
used for identifying component retention times and quantification of inosine found in test 
samples.  Using UV detection at 240 nm, component peak area and external 
standardization were used for inosine computations.  For determining inosine AUC on test 
samples, the trapezoidal rule computation using Excel software was performed on inosine 
sample values from 0 to 20 min. 
2.3 Results and Discussion 
2.3.1 Additional Evaluation for Hydroxyl (·OH) Free Radicals 
 During periods of cardiac oxidative stress (e.g. acute myocardial infarction), the 
heart is deprived of the oxygen needed for ATP synthesis.  In the absence of oxygen 
dormant enzymes activate whereby ATP is sequentially converted to ADP, AMP, 
adenosine, inosine and hypoxanthine.  Upon reperfusion of the heart with oxygenated 
blood or oxygenated Krebs solution, additional cellular enzymatic conversions transpire 
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with xanthine oxidase converting hypoxanthine to xanthine and uric acid.  A metabolic by-
product of xanthine oxidase is the formation of hydrogen peroxide (H2O2) which is 
normally converted by glutathione peroxidase to H2O.  However, in the presence of Fe2+, 
H2O2 may be converted to a hydroxyl free radical (·OH) via the Fenton and Haber-Weiss 
reactions (Figure 3) [IUPAC, 1997]. 
 The (·OH) is a known potent reactive oxygen species (ROS) and can cause damage 
to cellular components (e.g. lipids, proteins, nucleic acids) [Tardif and Bourassa 2000].  To 
investigate the formation of ROS, one research objective was to evaluate and estimate the 
amount of (·OH) generated from 20 min of global cardiac ischemia using isolated mouse 
hearts.  In several of the initial experiments, SA [1 mM] was fortified in the Krebs buffer 
solution (pH adjusted 7.4) to react with (·OH) and form the reaction products of 2,3 and 
2,5-DHBA isomers [Onodera et al., 1991; Coudray et al., 2000]. 
The HPLC-DAD conditions that were used for inosine determination resolved 
prepared standards [13 ng/mL or 86 nM] of the 2,3 and 2,5-DHBA isomers from other 
Krebs eluant sample components (e.g. SA, adenosine, inosine, hypoxanthine etc.).  
However, in our experiments performed using SA, we did not observe either the 2,3 or 2,5-
DHBA isomers in the sample chromatograms from mouse hearts that were subjected to 
global cardiac ischemia.  It is possible that the initial level of SA [1 mM] added to the 
Krebs buffer solution increased the total solute concentration to a level, which reduced the 
solubility of 2,3 and 2,5-DHBA isomers and therefore made each analytically undetectable.  
Lower concentrations of SA [e.g. ≤ 1 µM] may in theory resolve this aspect of ROS 
generation from mouse acute global cardiac ischemia. 
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Figure 3. Schematic drawing of cardiac cellular ATP catabolism due to oxidative stress 
and potential oxygen reperfusion injury due to (·OH) free radical generation. 
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2.3.2 HPLC-DAD and HPLC-MS Identification 
 The HPLC-DAD method was used for determining all of the following components 
(adenosine, inosine, hypoxanthine, xanthine, uric acid, 2,3-DHBA and 2,5-DHBA 
isomers).  The mobile phase aqueous component 0.05% TFA in deionized water was 
chosen as pH ~2.3 provided good peak shapes on all components and a low pH was 
necessary to reduce peak tailing on the acidic components (e.g. 2,5-DHBA has pKa ≈ 2.9).  
The Synergi™ Hydro-RP C18 (polar endcapped) and Synergi™ Polar-RP C18 (ether-linked 
phenyl) columns of identical dimensions were evaluated for use.  While both columns 
worked well for inosine and polar components (e.g. adenosine), the Synergi™ Hydro-RP 
C18 was selected for overall analysis as it provided good component peak shape and 
sufficient resolution of all components. 
 Other components evaluated using this method have HPLC retention times as 
follows (uric acid 2.8 min, hypoxanthine 3.9 min, xanthine 4.2 min, adenosine 5.7 min, 
CK-MB 8.2 min, 2,3-DHBA 8.4 min, 2,5-DHBA 10.2 min, myoglobin 14.1 min, atrial 
natriuretic peptide 14.5 min, brain natriuretic peptide 15.0 min and salicylic acid 15.4 
min). Both cardiac troponin I and troponin T were not detected using this HPLC method.  
An HPLC-DAD chromatograms overlay from a mouse subjected to 20 min acute global 
cardiac ischemia and a control mouse (non-ischemia) are presented in Figure 4 with 
inosine elution at 5.9 min. 
 To evaluate perfusate sample stability, the prepared samples were initially injected 
and analyzed by HPLC-DAD.  The samples were subsequently stored overnight on the 
autosampler at ambient lab temperature and re-injected (n=3 times) to evaluate both for 
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Figure 4. HPLC-DAD chromatograms overlay of control (025-2501.D) and 20 min global 
cardiac ischemia (026-2601.D) mouse perfusate samples.  Inosine (RT 5.9 min) and 
HPLC-ESI/MS mass spectrum identifying inosine (MW 268 Da) as a potential early 
biomarker of global cardiac ischemia is demonstrated in the ischemic mouse heart 
perfusate.  The chromatogram overlay between control and 20 min global cardiac ischemia 
also demonstrates consistent gradient repeatability. 
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changes in component levels due to possible synthesis or degradation reactions from 
potential enzymes eluted in the perfusate and to evaluate instrument precision.  In all re-
injected perfusate samples, component levels remained constant (≤ 4% RSD) indicating 
stability overnight at ambient temperature and the absence of appreciable levels of 
nucleoside and purine converting enzymes in the perfusate. 
2.3.3 HPLC-MS Identification of Inosine as Potential Initial Ischemia Biomarker 
 An HPLC-MS was used to identify inosine at retention time 5.9 min in samples 
from test mice subjected to oxidative stress.  The HPLC analytical column, mobile phase 
gradient and flow rate were identical to that used in the HPLC-DAD method.  The mass 
spectrum for inosine (MW 268 Da) is presented in Figure 4.  It was acquired using the MS 
positive ion mode, which provided a good mass spectral quality match against a prepared 
standard of inosine in Krebs buffer solution.  The full scan spectrum was achieved using 
up-front collision induced dissociation (CID) and nitrogen as the collision gas.  The mass 
spectrum base peak (137 Da) represents the cleavage of the ribose entity from inosine 
leaving a protonated hypoxanthine (MW 136 Da) (Figure 5). 
2.3.4 Evaluation of Inosine AUC and Other Cardiovascular Parameters 
 Initially, the focus was on identifying cardiac protein or peptide biomarkers (e.g. 
ANP, BNP) that may be released from ischemic myocardium; however in comparison with 
non-ischemic mouse hearts only inosine (22 to 69 fold) and xanthine-like products (e.g. 
hypoxanthine (>7 fold), xanthine (~3 fold), uric acid (~3 fold)) were found at higher levels 
in globally ischemic mouse hearts.  Figure 6 is a profile of mouse hearts subjected to 
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Figure 5. HPLC-ESI/MS positive ionization mode of inosine (MW 268 Da) with 
fragmentation to hypoxanthine (MW 136 Da). 
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Hypoxanthine (M+1) – 137 Daltons
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Figure 6.  Profile of the mean (±SD) ATP catabolic by-products detected in Krebs solution 
versus reperfusion time after 20 min mouse global cardiac ischemia (n=6 mice).  Control 
mice (n=6, non-ischemia) are not plotted with undetectable levels of ATP catabolic by-
products in all sample time points (0, 1, 3, 5, 10 and 20 min). 
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oxidative stress with individual ATP degradation by-product components (mean ± SD) 
plotted against Krebs buffer reperfusion time.  As can be seen in Figure 6, inosine was the 
component which had the highest response with detectable component amounts found at 
low µM levels, after 20 min global cardiac ischemia (n=6 mice).  The control mice (n=6, 
non-ischemia) are not shown, as there were undetectable levels of all ATP catabolic by-
products in each sample time point (0, 1, 3, 5, 10 and 20 min). 
 Cardiovascular parameter (e.g. percent cardiac ventricular functional recovery) was 
measured and reported with the calculated inosine AUC results (Table 5).  As can be seen 
from Table 5, inosine efflux was present in test mouse heart perfusate samples which were 
subjected to oxidative stress and was not detected in control mouse heart perfusate 
samples.  However, for both controls and test mice, the percent cardiac functional recovery 
ranged from 39 to 92% with the lowest measured cardiac functional recovery being in test 
mouse hearts which had the largest amount of inosine present in the Krebs buffer solution 
(e.g. test mouse with 2, 469 ng min ml-1 AUC inosine effluxed with 39% cardiac 
functional recovery).  This may indicate that mouse hearts which are injured to a greater 
degree from the effects of oxidative stress efflux more inosine from ATP by- product 
degradation.  Further studies with larger test and control mouse sample size (e.g. n=10) 
would be necessary to statistically interpret this observation. 
2.4 Conclusion 
 The preliminary results suggest that the concentration of inosine found in test 
animals subjected to cardiac oxidative stress may serve as a potential biomarker indicative 
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Table 5. Inosine washout and cardiac ventricular functional recovery in Langendorff 
mouse hearts following aerobic perfusion and 20 min global ischemia. 
 
Sample 
Type 
Inosine AUC 0-20 min 
[ng min / mL] 
% Cardiac 
Functional 
Recovery 
Control N.D. 70 
Control N.D. 72 
Control N.D. 74 
Control N.D. 82 
Control N.D. 81 
Control N.D. 64 
Test 653 92 
Test 962 84 
Test 954 77 
Test 1,003 53 
Test 2,469 39 
Test 2,583 52 
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of early cardiac ischemia.  This can be explained by ischemic myocytes undergoing 
nucleotide purine catabolism in the absence of oxygen with subsequent activation of 
dormant cellular enzymes and generation of degradative breakdown products of ATP.  
Preliminary human studies will need to be undertaken to determine the validity of this 
hypothesis. 
 Additional research from our group will be performed on plasma samples obtained 
from hospital admitted patients suspected of undergoing acute myocardial infarction to 
determine if plasma levels of endogenous inosine are significantly elevated during periods 
of cardiac oxidative stress.  If inosine plasma levels are found to be significantly elevated 
in samples obtained from patients undergoing acute myocardial infarction, inosine should 
be recommended as a potential biomarker for the initial cardiac ischemic event, and may 
be useful in indicating the need for immediate medical treatment, potentially improving 
patient outcome. 
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CHAPTER 3. Animal Studies to Evaluate Salicylic Acid, “Effects of 
Salicylic Acid on Post-Ischemic Ventricular Function and Purine Efflux 
in Isolated Mouse Hearts” 
 
 
 
3.1 Introduction 
 
 Aspirin (acetyl salicylic acid, ASA) is one of the most widely used drugs in the 
world and has been used for many years for its analgesic, anti-pyretic, anti-inflammatory 
and anti-platelet (blood thinning) properties (Vane et al., 2003; Schror, 1997; Evans et al., 
1968).  ASA (160 or 325 mg dose) is routinely administered with other cardiac 
medications as part of initial emergency treatments to patients presenting with chest pain 
and potential acute myocardial infarction (MI) to inhibit platelet aggregation at the site of 
cardiac thrombosis (Feldman et al., 1999; Antman et al., 2004; Abarbanell et al., 2001; 
Kosowsky, 2006).  A 325 mg dose of aspirin can have plasma concentration maximums 
(Cmax) of 67 µM acetyl salicylic acid and 188 µM salicylic acid (Merck 11th Edition, 
1989).  Aspirin is also used chronically by many individuals for other medical conditions, 
with plasma salicylic acid concentrations ranging from 145 to 725 µM (analgesia) and 
1,086 to 2,172 µM (anti-inflammatory) (Moffat et al. 1986). 
 Aspirin’s mechanism of action is well documented with interactions causing 
irreversible inhibition of both cyclooxygenase isoenzymes (COX-1, COX-2) (Smith et al., 
1971; Schror, 1997).  The mechanism for ASA inhibiting platelet aggregation is through 
irreversible acetylation of the COX-1 enzyme which blocks synthesis of thromboxane A2, 
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a platelet aggregator and vasoconstrictor (Vane et al., 2003).  Other reported medical uses 
of ASA require higher blood concentrations (e.g. a rheumatoid arthritis patient may require 
1.5 to 2.5 mM ASA and an anti-inflammatory dose may require sodium salicylate levels of 
0.5 to 5 mM) (Nulton-Persson et al., 2004; Smith et al., 1971).  In humans, ASA is rapidly 
metabolized (half-life ~3-4 hrs) and excreted via phase I metabolism (60% via 
deacetylation to salicylic acid (SA)) and phase II metabolism (~ 40% via conjugated 
products) (Rowland et al., 1968). 
 In addition a recent publication reported inhibitory effects of both ASA and SA on 
rat cardiac mitochondrial respiration (Nulton-Persson et al., 2004).  These authors found 
that ASA and SA both could reduce NADH supply to the electron transport chain in 
isolated rat cardiac mitochondria, thus reducing ATP synthesis (via inhibition of oxidative 
phosphorylation).  They also demonstrated a negative dose-response effect from both ASA 
and SA (0-10 mM concentration range) on cardiac mitochondrial respiration under non-
ischemic conditions.  Other research was performed demonstrating the inhibitory effects of 
ASA and SA on xanthine oxidase, which would inhibit enzymatic conversion of 
hypoxanthine to xanthine and uric acid (Carlin et al., 1985; Masuoka and Kubo, 2003). 
To this context, the present study was designed to further examine the effects of SA 
(0, 0.1 and 1.0 mM) on ATP catabolic by-products (e.g. inosine and hypoxanthine) along 
with an indirect evaluation of purine nucleoside phosphorylase (PNP) enzyme activity 
(indicated by inosine/hypoxanthine conversion ratio).  We hypothesized that higher 
concentrations of SA (e.g. 1.0 mM) coupled with periods of acute cardiac ischemia may 
potentiate the ischemic adverse effects on heart tissue via increased uncoupling of 
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oxidative phosphorylation and subsequently enhanced efflux of ATP catabolic by-products 
such as inosine, which has been proposed in our recent publication (Farthing et al., 2006) 
as a potential biomarker of acute cardiac ischemia.  The morphometric characteristics and 
baseline cardiac function data from controls (non-ischemic and without SA) and test 
(ischemic and without SA) animals from Chapter 2 research were used for statistical 
comparisons to the experimental groups exposed to SA in this chapter of research. 
3.2 Experimental 
3.2.1 Chemicals, Standards and Krebs Buffer Solution 
 All experimental chemicals were purchased and solutions prepared as per our 
recent published work (Farthing et al., 2006).  Briefly, ACS grade or better purity 
hypoxanthine, xanthine, trifluoroacetic acid (TFA) and methanol (Optima) were purchased 
from Acros Organics (Fair Lawn, NJ, USA).  Salicylic acid, adenosine, inosine, uric acid, 
sodium chloride, sodium bicarbonate, potassium chloride, magnesium sulfate, monobasic 
potassium dihydrogen phosphate, dextrose, ethylenediaminetetraacidic acid (EDTA) and 
calcium chloride were all purchased from Sigma-Aldrich (St. Louis, MO, USA). 
 Stock and working standards of adenosine (374.2 µM), inosine (372.8 µM), 
hypoxanthine (734.7 µM), xanthine (657.4 µM) and uric acid (594.8 µM) were prepared in 
deionized water and stored at 4°C as per work (Farthing et al., 2007).  The working 
standards were maintained at -20°C along with the mouse Krebs buffer perfusate samples 
and demonstrated stability for at least 6 months.  The Krebs buffer solution consisted of 
either 0, 0.1 or 1.0 mM SA and 118.5 mM NaCl, 25.0 mM NaHCO3, 11.1 mM C6H6O6, 4.7 
mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 0.5 mM EDTA and 2.5 mM CaCl2 using in-
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house prepared deionized water (final pH 7.4 and continuously gassed with 
95%O2:5%CO2 during the isolated heart experiments).  For HPLC analysis, deionized 
water (18 MΏ-cm) used was produced and filtered using US Filter Purelab Ultra deionized 
water system (Lowell, MA, USA). 
3.2.2 Langendorff Isolated Mouse Heart Preparation and Experimental Protocols 
 All animal experimental conditions were similar to our published work (Farthing et 
al., 2006; Xi et al., 1998).  Adult male mice (ICR strain) were used for all cardiac ischemia 
experiments with morphometric characteristics, baseline cardiac function, and ANOVA 
results presented in Table 6.  The protocol for Groups II, III, and IV consisted of 30 min of 
stabilization, 20 min of zero-flow global ischemia and 30 min of reperfusion (Figure 7).  
Time-matched normoxic perfusion (for 80 min) was carried out for the Control group and 
Group I.  Briefly, the mice were anaesthetized; hearts quickly isolated and cannulated onto 
a Langendorff apparatus within 3 min.  Following the 30 min of stabilization period, global 
ischemia was accomplished by stopping heart perfusion inflow for 20 min.  Upon heart 
reperfusion, approximately 1.5 mL samples of Krebs buffered perfusate from the isolated 
mouse hearts were collected at predetermined time-points (0, 1, 3, 5, 10 and 20 min) into 
plastic bullet centrifuge tubes and immediately frozen at -20°C.  At the end of each 
experiment, the heart was removed from the Langendorff system and quickly weighed. 
 The present study measured simultaneously both cardiovascular parameters (e.g. 
coronary flow rate, heart rate and cardiac developed force) and efflux of ATP catabolic by-
products (e.g. inosine and hypoxanthine evaluated in Krebs perfusate samples) for each of 
the experimental groups.  The control group consisted of six aerobically perfused hearts 
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Table 6. Morphometric characteristics and baseline cardiac function of the adult mice (ICR 
strain). 
 
_________________________________________________________________________________________         _____________ 
   Control  Group I  Group II  Group III  Group IV 
   (n = 6)   (n = 6)                   (n = 6)    (n = 6)    (n = 6) 
______________________________________________________________________________  ____________________________ 
 
Body Weight (g)  42.2 ± 1.3  37.0 ± 0.9  38.7 ± 2.1  41.5 ± 2.7  36.1 ± 1.3 
Heart Wet Weight (mg) 258 ± 6  243 ± 16  242 ± 14  252 ± 18  258 ± 20 
Heart Rate (bpm)  368 ± 23  340± 26  345 ± 23  368 ± 37  373± 17 
Developed Force (g)  0.81 ± 0.19 1.06 ± 0.27 1.12 ± 0.12 1.09 ± 0.23 0.77 ± 0.16 
Rate-Force Product (g x bpm) 308 ± 80  361 ± 109  372 ± 49  411 ± 107  287 ± 65 
Coronary Flow (ml/min) 2.3 ± 0.2  2.3 ± 0.3  1.7 ± 0.1  2.1 ± 0.2  2.7 ± 0.3 
___________________________________________________________________________________________________________ 
 
Values are mean ± SEM.  No significant difference (P<0.05, one-way ANOVA) between 
the groups were found for the listed parameters. 
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Figure 7.  Protocol for animal experiments depicting experimental groups, salicylic acid 
(SA) level, ischemic condition and coronary effluent sample time points. 
 79
which were not subjected to ischemia and used non-SA Krebs buffer (Farthing et al., 
2006).  Group I consisted of six hearts which were not subjected to global cardiac 
ischemia; however the Krebs buffer solution contained 1.0 mM SA to evaluate the effects 
of the highest tested concentration of SA on ATP catabolism and PNP activity.  Group II 
consisted of six hearts which were subjected to global cardiac ischemia with the Krebs 
buffer solution not containing SA to evaluate the effects of ischemic conditions on ATP 
catabolic by-products.  To determine if the effects of SA are dose-dependent in the hearts 
undergoing global cardiac ischemia, Group III consisted of six hearts which were subjected 
to Krebs buffer solution containing 0.1 mM SA and Group IV consisted of six hearts 
subjected to 1.0 mM SA. 
3.2.3 HPLC-UV Conditions and Mobile Phase 
 All instrument conditions were performed as previously reported (Farthing et al., 
2007).  Briefly, the HPLC-UV method used a Phenomenex® Onyx™ monolithic C18 
analytical column (20 cm x 4.6 mm I.D., 130 Å) and Onyx™ C18 guard column (5 cm x 4.6 
mm I.D.) (Torrance CA, USA).  The mobile phase gradient consisted of aqueous 
trifluoroacetic acid (0.1% TFA in deionized water, pH 2.2, v/v) and methanol with time 
course (1 to 20% methanol linear gradient over 10 min).  The mobile phase flow-rate was 
1.0 ml/min with operating pressure of ~84 bar at ambient column temperature.  A 15 µl 
direct injection of the Krebs buffer perfusate sample was made with optimal UV 
wavelength absorption of 250 nm used for inosine and hypoxanthine detection. 
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3.2.4 Data Computation and Statistics 
 The HPLC data acquisition and component computations were performed using 
TotalChrom™ Workstation software (Perkin Elmer™, Norwalk, CT, USA).  Statistics 
utilizing ANOVA to compare the multi-group experimental results was performed using 
MS Excel (Microsoft®, Seattle, WA, USA) and post hoc analysis (Dunnett, Tukey) using 
JMP 6.0 (SAS Institute Inc., Cary, NC, USA) with α=0.05 and P<0.05 demonstrating 
significance.  The Dunnett post hoc analysis was performed to compare each experimental 
test group’s mean result to a control group’s mean result.  In addition, the Tukey post hoc 
analysis was also performed as it compares each group’s mean result to each of the other 
group’s mean result.  However, it should be emphasized that for these non-parametric 
analysis, the small sample size (n=6 each group) for these animal experiments may be a 
limitation when interpreting the results.  Correlation evaluation was performed using 
GraphPad Prism 4 (San Diego, CA, USA).  For determining total effluxed inosine, the area 
under the curve (AUC) was calculated utilizing trapezoidal rule computations and MS 
Excel on HPLC results (0 to 20 min time point perfusate samples). 
3.3 Results and Discussion 
3.3.1 Chromatography and Method Validation 
 Figure 8 shows representative chromatograms for: (A) low standard of 
hypoxanthine (1.8 µM) and inosine (0.9 µM) in deionized water; (B) standard of 
hypoxanthine (14.7 µM, RT ~5.2 min), uric acid (11.9 µM, RT ~5.6 in), xanthine (13.1 
µM, RT ~6.7 min), adenosine (7.5 µM, RT ~10.3 min) and inosine (7.5 µM, RT ~10.5 
min) in deionized water; (C) Group I (no ischemia + 1.0 mM SA) perfusate sample  
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Figure 8. Chromatograms representing (A) low standard of 1.8 µM hypoxanthine (Hypo, 
RT 5.2 min) and 0.9 µM inosine (Ino, RT 10.6 min) in deionized water, (B) standard of 
14.7 µM hypoxanthine, 11.9 µM uric acid (UA, RT 5.6 min), 13.1 µM xanthine (Xan, RT 
6.7 min), 7.5 µM adenosine (Adeno, RT 10.3 min) and 7.5 µM inosine in deionized water, 
(C) Group I mouse perfusate sample (no ischemia and 1.0 mM SA), (D) Group II perfusate 
sample (20 min global ischemia and no SA), (E) Group III mouse perfusate sample (20 
min global ischemia and 0.1 mM SA) and (F) Group IV mouse perfusate sample (20 min 
global ischemia and 1.0 mM SA). 
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mV 
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collected at 1 min of aerobic perfusion, (D) Group II (ischemia + 0 mM SA) perfusate 
sample collected at 1 min of reperfusion; (E) Group III (ischemia + 0.1 mM SA) perfusate 
sample collected at 1 min of reperfusion; and (F) Group IV (ischemia + 1.0 mM SA) 
perfusate sample collected at 1 min of reperfusion. 
As demonstrated by the chromatograms, the HPLC method provided sufficient 
sensitivity (Figure 8A) and selectivity (Figure 8B) for each of the ATP catabolic by-
products.  Figures 8C, 8D, 8E and 8F demonstrate how changes in experimental conditions 
(ischemia and SA concentrations) resulted in increased concentrations of inosine and 
hypoxanthine effluxed from the heart.  Particularly Figures 8E and 8F demonstrate higher 
levels of ATP catabolic by-products suggesting the presence of SA in the Krebs buffer 
exacerbates ATP uncoupling only in the ischemic mouse hearts.  It is also noteworthy that 
the heart subjected to ischemia under 1.0 mM SA (Group IV, Figure 8F)  
had elevated levels of ATP catabolic by-product adenosine, which is the nucleoside 
precursor to inosine and indicative of the largest total amount of ATP catabolic by-
products effluxed due to the effect of 1.0 mM SA on the ischemic heart.  All 
chromatograms obtained from animal reperfusates using SA in the Krebs buffer solution 
lacked detectable levels of xanthine and uric acid components, thus supporting published 
research citing ASA and SA inhibitory effects on the XO enzyme (Carlin et al., 1985; 
Masuoka et al., 2003). 
Method validation was performed as described in our previous publication 
(Farthing et al., 2007) and in summary, the method demonstrated sufficient linearity of the 
calibration standards (inosine curve 0.9-18.6 µM, hypoxanthine curve 1.8-36.7 µM, with 
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R>0.9990 for each component) and method detection limits of 0.4 µM (inosine) and 0.7 
µM (hypoxanthine).  Method accuracy and precision for inosine and hypoxanthine was 
determined using quality control samples (n=15) with acceptable combined intra-day and 
inter-day component accuracy (±6 % error) and precision (±8.1 % CV).  To demonstrate 
component stability, re-injections of the animal perfusate samples were made after sitting 
on the HPLC autosampler overnight at lab ambient temperature and again after long term 
storage.  Both inosine and hypoxanthine in animal perfusate demonstrated excellent 
stability overnight on the HPLC autosampler and for more than 6 months when stored at 
-20°C. 
3.3.2 Effect of Salicylic Acid on Purine Efflux 
 Table 7 lists mean (SEM) inosine and hypoxanthine concentrations for the mouse 
hearts representing each of the 5 experimental groups.  As shown in Figure 9, Control 
group without both cardiac ischemia and SA (Farthing et al., 2006) and Group I (non-
ischemic hearts but using 1.0 mM SA, the highest tested SA concentration) did not have 
detectable amounts of ATP catabolic by-products.  However, inosine levels for Groups II, 
III and IV (all underwent global ischemia) had significantly elevated total inosine efflux of 
1,437±348, 3,872±900, and 12,575±3319 ng/mL/min respectively (mean ± SEM, Figure 
9), i.e. Groups II (P<0.05), III (P<0.05), and IV (P<0.01) as compared with the Control 
group (Dunnett test).  These inosine results demonstrate that SA concentrations increased 
ATP catabolism under our conditions of acute global cardiac ischemia with groups III and 
IV mean total effluxed inosine levels potentiated above group II by approximately 2.7-fold 
and 8.8-fold, respectively. 
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Table 7. Table with mean (SEM) inosine and hypoxanthine concentrations and 
inosine/hypoxanthine ratios under various experimental conditions (control and global 
cardiac ischemia) and concentrations of salicylic acid in Krebs buffer (0, 0.1 and 1.0 mM). 
Sample Ischemia
Reperfusion 
Time (min)
Mean 
Hypoxanthine 
[µM]
SEM 
Hypoxanthine
Mean Inosine 
[µM]
SEM 
Inosine
Inosine/Hypoxanthine 
ratio
Krebs 
Salicylic 
Acid Level
Control No 0 0 0 0 0 N/A 0  mM SA
(n=6) 1 0 0 0 0 N/A
3 0 0 0 0 N/A
5 0 0 0 0 N/A
10 0 0 0 0 N/A
20 0 0 0 0 N/A
Group I No 0 0 0 0 0 N/A 1.0 mM SA
(n=6) 1 0 0 0 0 N/A
3 0 0 0 0 N/A
5 0 0 0 0 N/A
10 0 0 0 0 N/A
20 0 0 0 0 N/A
Group II Yes 0 2.8 2.0 1.2 2.0 0.4 0 mM SA
(n=6) 1 111.5 0.6 200.9 0.6 1.8
3 29.4 0.6 41.7 0.6 1.4
5 9.7 2.0 16.9 1.0 1.7
10 9.7 2.0 15.5 1.2 1.6
20 2.8 2.0 2.6 1.2 0.9
Group III Yes 0 0 0 0 0 N/A 0.1 mM SA
(n=6) 1 230.7 0.7 391.5 0.5 1.7
3 83.0 0.4 117.8 0.4 1.4
5 38.9 1.4 53.7 0.8 0
10 38.9 1.4 49.6 1.0 0
20 11.0 1.4 4.5 1.4 0
Group IV Yes 0 15.4 1.5 12.9 1.5 0.8 1.0 mM SA
(n=6) 1 183.2 1.1 761.3 1.1 4.2
3 89.2 1.2 240.0 1.5 2.7
5 46.3 1.4 85.4 1.6 1.8
10 20.9 1.4 19.1 1.3 0.9
20 14.2 1.5 10.7 1.5 0.8  
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Figure 9. Bar chart representing total effluxed inosine (mean + SEM) for control (Ctrl), 
Group I, Group II, Group III and Group IV experimental conditions.  Groups II, III and IV 
demonstrated statistical significance (* is p<0.05, ** is p<0.01) from Ctrl (Dunnett test) 
and Group I (Tukey test).  Ctrl (no ischemia and no SA), Group I (no ischemia and 1.0 mM 
SA), Group II (20 min global ischemia and no SA), Group III (20 min global ischemia and 
0.1 mM SA) and Group IV (20 min global ischemia and 1.0 mM SA). 
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 It should be noted that we did not observe any ATP catabolic by-products from 
group I animals (1.0 mM SA and non-ischemic).  Based on published work (Nulton-
Persson et al., 2004; Cronstein et al., 1994), we suspected that in the presence of 1.0 mM 
SA we might observe low concentrations of ATP catabolic by-products even under non-
ischemic conditions.  However, we did not observe either inosine or hypoxanthine in 
detectable levels from any perfusate samples from this experiment group.  One possible 
explanation is that these authors used cardiac mitochondrial preparations for their studies 
and not the entire heart tissue as did our study.  They reported 1.0 mM SA uncoupling 
oxidative phosphorylation by approximately 20% (using oxygen electrode and α-
ketoglutarate dehydrogenase enzyme analysis) which may not produce high enough 
concentrations of ATP metabolites to activate the normally dormant adenosine deaminase 
and PNP enzymes, thus inosine and hypoxanthine would not be produced and detected.  
Using SA and ischemic conditions together would combine the effects of SA (ATP 
decoupling) and ischemia (blocks ATP synthesis) and lead to significant reduction in 
cellular ATP concentration and the potentiated effluxed levels of inosine observed in our 
present study. 
3.3.3 Effect of Salicylic Acid on Cardiac Function 
Figure 10 bar charts (mean ± SEM) demonstrate the effects of SA on cardiac 
functional parameters (DF, HR, RFP).  No significant differences were found in HR for all 
experimental conditions.  For DF and RFP, significance (P<0.05, Tukey test) was 
demonstrated between Groups III and IV relative to each other but neither group was 
statistically different than control (Dunnett test).  Cardiac DF and RFP were slightly 
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Figure 10. Bar chart representing mean ± SEM for cardiac developed force (DF), heart rate 
(HR) and rate-force product (RFP) at the end of 30 min reperfusion for each of the 
experimental groups.  Developed force and RFP on Groups III and IV demonstrated 
statistical significance (* is p<0.05, Tukey test) between each other, however neither 
demonstrated significance from control (Ctrl) (Dunnett test) nor Group I (Tukey test).  
Control (no ischemia and no SA), Group I (no ischemia and 1.0 mM SA), Group II (20 
min global ischemia and no SA), Group III (20 min global ischemia and 0.1 mM SA) and 
Group IV (20 min global ischemia and 1.0 mM SA). 
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increased (beneficial) at the 0.1 mM SA concentration, but adversely affected at 1.0 mM 
SA.  Theses results demonstrate that under conditions of acute global cardiac ischemia, 
higher levels of SA in the Krebs buffer exhibited an increasing relationship on effluxed 
inosine; however a beneficial then adverse effect on DF and RFP was observed.  These 
results have confirmed the previously reported positive inotropic effects of ASA on cardiac 
contractility through inhibiting COX enzymes and in turn prostaglandin synthesis 
(Karmazyn, 1986) and through its modulating effects on cellular calcium levels 
(Molderings et al., 1987). 
3.3.4 Non-Linear Relationship of Inosine Efflux and Cardiac Contractile Function 
Following Ischemia 
Figure 11 is a correlation plot which demonstrates the lack of correlation between 
total effluxed inosine (in Groups II, III and IV) and DF or FRP, with r2 (coefficient of 
determination) values of 0.52 and 0.59, respectively.  This non-linear relationship can be 
explained by an apparent beneficial effect of 0.1 mM SA on heart contractility, yet an 
adverse effect at 1.0 mM SA, while total effluxed inosine increased with increasing SA 
concentrations.  Therefore, whereas the inosine efflux concentration could serve as a 
sensitive biomarker for acute cardiac ischemia, it appears to be a poor predictor of the 
individual post-ischemic cardiac functional recovery, at least in this ex vivo model. 
3.3.5 Effect of Salicylic Acid on Purine Nucleoside Phosphorylase Activity 
 Figure 12 illustrates the ATP catabolic by-products resulting from acute cardiac 
ischemic conditions.  Normally dormant enzymes in heart tissue (e.g. adenosine  
 89
Figure 11.  Correlation plot demonstrating lack of significant linear correlation between 
total effluxed inosine (AUC) and DF or RFP in the ischemic mouse hearts under various 
SA concentrations (0, 0.1 and 1.0 mM).  Group II (20 min global ischemia and no SA), 
Group III (20 min global ischemia and 0.1 mM SA) and Group IV (20 min global ischemia 
and 1.0 mM SA). 
0 3 0 0 0 6 0 0 0 9 0 0 0 1 2 0 0 0 1 5 0 0 0 1 8 0 0 0
0
2 5
5 0
7 5
1 0 0
r 2 = 0 . 5 2
P = 0 . 4 9
G r o u p  I I
G r o u p  II I
G r o u p  IV
I n o s i n e  A U C ( n g /m l /m in )
D
ev
el
op
ed
 F
or
ce
(%
 o
f P
re
-Is
ch
 B
as
el
in
e
)
0 3 0 0 0 6 0 0 0 9 0 0 0 1 2 0 0 0 1 5 0 0 0 1 8 0 0 0
0
2 5
5 0
7 5
1 0 0
r 2 = 0 . 5 9
P = 0 . 4 4
G r o u p  I I
G r o u p  II I
G r o u p  IV
I n o s i n e  A U C ( n g / m l / m i n )
R
at
e
-F
o
rc
e
 P
ro
d
u
ct
(%
 o
f 
Pr
e
-Is
ch
 B
as
e
lin
e
)
 90
 
 
N
O
NH N
N
O N
H
O
NH N
H
N O N
H
O
NH
N
N
O
O N N
N
N
N
O
H
N
N N
N
O
O2,H2O H2O2 O2,H2O H2O2
OH2 NH3
OH2
Pi
OH2
Pi
OH2 NH3
H
Hypoxanthine
Xanthine Uric Acid
HO   OH
HO
Adenosine
HO   OH
HO
Inosine
2
H
adenosine
deaminase
purine nucleside
phosphorylase
xanthine
oxidase xanthineoxidase
 adenylate deaminase
Cellular
  AMP
Hypoxanthine
H
H
IMP
nucleotidase
5' - nucleotidase
Pi Ribose-1-P
xanthine
dehydrogenase
xanthine
dehydrogenase
NAD+ NADH NAD+ NADH
 
Figure 12. Biochemical pathway of ATP catabolic by-products resulting from global acute 
cardiac ischemia. 
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deaminase, purine nucleoside phosphorylase) are activated due to cellular buildup of ATP 
catabolic by-products (e.g. ADP, AMP).  Under our experimental conditions, inosine and 
hypoxanthine were the primary effluxed by-products of ATP catabolism.  In observation of 
the larger amounts of total inosine effluxed in our 1.0 mM SA perfusate samples, we 
wanted to investigate if SA had a negative effect (inhibitory) on PNP enzyme activity 
which might account for the potentiated effluxed inosine levels. 
 The PNP enzyme activity under ischemic conditions can be indirectly determined 
by calculating the conversion of inosine to hypoxanthine ratio on each perfusate sample.  
Table 7 lists the inosine [µM]/hypoxanthine [µM] (ino/hypo) conversion ratio for the 
experimental groups.  In Group II (ischemia, 0 mM SA), the ino/hypo mean conversion 
ratio was approximately ~1.3.  Under Group IV experimental conditions (ischemia, 1.0 
mM SA), the ino/hypo conversion ratios were not constant with the perfusate sample 
collected at 1 min of reperfusion having the largest ino/hypo ratio, and at the subsequent 
time points returning to a more constant ino/hypo conversion ratio (~0.9) (Figure 13). 
 These results can be explained by two effects occurring simultaneously when using 
both SA and ischemia conditions.  Cardiac ischemic (anaerobic) conditions can cause ATP 
catabolism as demonstrated in our previous work (Farthing et al., 2006), while SA has 
been reported to cause decoupling of cardiac mitochondrial respiration (Nulton-Persson et 
al., 2004).  Both situations may contribute to the increase in ATP catabolic by-products as 
heart muscle contractions require significant amounts of ATP as its primary energy source.  
This leads to cellular buildups of ADP and AMP metabolic by-products as ATP is not able 
to be regenerated (via salvage pathway) or synthesized, thus ATP catabolism occurs to 
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eliminate the cellular buildup of by-products.  As aerobic conditions to the heart tissue was 
reestablished via reperfusion, the ino/hypo conversion ratio returns to a more constant 
conversion ratio (e.g. ~0.9).  The conversion ratio drops to zero as aerobic conditions 
should deactivate ADA and PNP enzymes in the cardiac myocytes, thus inhibiting ATP 
catabolism (Figure 13). 
3.3.6 Potential Clinical Relevance 
 Since both ASA and SA have been reported to uncouple mitochondrial respiration 
under aerobic conditions and in turn to inhibit ATP synthesis (Nulton-Persson et al., 2004) 
and our current study demonstrates a potentiated ATP catabolism by SA under cardiac 
ischemia, it is possible that current use of ASA for medical emergency treatment in acute 
cardiac ischemic situations (e.g. acute MI) may potentially increase the ischemia-caused 
ATP catabolism and inosine efflux. 
While standardized doses of ASA (160 to 325 mg) are used to inhibit platelet 
aggregation at the site of thrombus as part of the treatment for acute MI, the higher 325 mg 
dose equates to a potential Cmax of 67 µM acetyl salicylic acid and 188 µM salicylic acid 
blood concentrations.  Even with its significant protein binding (e.g. albumin), the 
augmented free drug levels of ASA and its metabolite SA may have an inhibitory effect on 
cardiac ATP production during the periods of acute cardiac ischemia.  The SA-induced 
enhancement of inosine efflux should also be taken into consideration when we analyze 
and interpret the patient’s plasma inosine level as a potential biomarker for acute cardiac 
ischemia (Farthing et al. 2006, 2007). 
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Figure 13. Plot of inosine [µM] to hypoxanthine[µM] (ino/hypo) conversion ratio versus 
reperfusion time (min).  The plot represents mean data from experimental conditions.  
Ino/hypo conversion ratio is highest in the 1 min reperfusion sample and returns to a 
constant ratio before dropping as aerobic conditions presumably deactivate ADA and PNP 
enzymes in the cardiac myocytes. 
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Whereas there are certainly positive benefits associated with using ASA as part of 
the treatment for acute MI patients to inhibit platelet aggregation at the site of thrombus, 
higher doses of ASA used for other medical conditions including analgesia (0.5 mM 
plasma salicylate) and rheumatoid arthritis (1.5 to 2.5 mM plasma salicylate) may actually 
aggravate the ischemic effects on heart tissue metabolism and ventricular contractile 
function, if the patients who have been using higher dose of ASA suddenly encounter acute 
cardiac ischemic events.  This animal research on isolated mouse hearts utilized SA levels 
of 0.1 and 1.0 mM, which were slightly lower but similar to expected blood concentrations 
in human patients utilizing aspirin as treatment for the above described medical conditions 
(e.g. acute MI, rheumatoid arthritis).  We suggest that further laboratory and clinical 
studies are warranted on the apparent adverse effects of higher concentrations of ASA and 
SA on ATP catabolism under acute cardiac ischemia, given the knowledge of how 
widespread ASA is used for its other medical benefits (e.g. analgesia, rheumatoid arthritis) 
and the possibility of those patients one day experiencing an acute cardiac  
ischemic event. 
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CHAPTER 4. Human Plasma Sample Evaluation, “An HPLC method for 
determination of inosine and hypoxanthine in human plasma from 
healthy volunteers and patients presenting with potential acute cardiac 
ischemia” 
 
 
 
4.1 Introduction 
 
The mouse model results from Chapter 2 research demonstrated significant levels 
of inosine and elevated levels of hypoxanthine effluxed from cardiac tissue subjected to 
constant conditions of oxidative stress (e.g. acute cardiac ischemia or myocardial 
infarction) (Farthing et al., 2006).  For this chapter of research, the HPLC method from 
Chapter 2 was modified and validated for the evaluation of human plasma samples, which 
are significantly more complex than Krebs perfusate samples from Chapter 2.    The 
purpose for the development of a plasma test method was to facilitate evaluation of the 
research hypothesis that non-traumatic chest pain patients potentially undergoing acute 
cardiac ischemia; should have elevated blood levels of ATP catabolic products (e.g. 
inosine and hypoxanthine) in their bloodstream, until medical treatment can succeed in 
restoring adequate blood flow to the oxygen deprived myocardium. 
Samples representing healthy individuals, hospital non-traumatic chest pain 
patients as well as other common vascular disease (e.g. congestive heart failure (CHF), 
hypertension (HT)) conditions were evaluated for inosine and hypoxanthine concentration 
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levels.  In addition, subject matched sample sets comprised of consecutive blood draws for 
plasma (heparin) and serum separator tube (SST), from healthy normal individuals were 
evaluated to determine if the blood draw matrix (e.g. anticoagulants, SST gel) affected 
inosine and hypoxanthine concentrations. 
Current test methods for endogenous cardiac biomarkers (e.g. cardiac troponin I, 
creatine kinase-MB and myoglobin) include LC-MS analysis (Bunk et al., 2000; Mayr et 
al. 2006) and fluorescence immunoassay (Apple et al., 1999; Heeschen et al., 1999; Apple 
et al., 2000; McCord et al., 2001); however elevation of these protein biomarkers reflect 
some level of myocardial necrosis, and are typically elevated in a diagnostic range several 
hours after acute myocardial infarction.  Current methods for plasma level measurement of 
selected ATP catabolic by-products such as inosine, hypoxanthine, xanthine and uric acid, 
in plasma utilize HPLC-UV with sample preparation steps including solid phase extraction 
(Feng et al., 2000), protein precipitations (e.g. ethanol or TCA) as well as some methods 
requiring use of an internal standard (Boulieu et al., 1983; Boulieu et al., 1984).  HPLC 
with ion pairing reagents (Scott et al., 1992; Furst et al., 1992; Tavazzi et al., 2005) or 
protein precipitation and enzyme catalyzed luminescence detection (Jabs et al., 1990) have 
also been used.  One HPLC method utilized centrifugal filtration for sample preparation; 
however their method did not completely resolve hypoxanthine and xanthine components 
at concentrations five times lower than our patient hypoxanthine concentrations, and with 
reported column degradation after three months of use (Severini et al., 1987). 
None of these techniques, however, offers as simple a determination for inosine 
and hypoxanthine (can also evaluate uric acid, adenosine, and xanthine) in human plasma 
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as the method detailed in this chapter of research.  The method utilizes centrifugal 
membrane filter technology and does not require the use of an internal standard.  In 
addition, this method employs a recently introduced HPLC column technology (Onyx™ 
monolithic column, Phenomenex® Inc. 2005 market introduction) (Phenomenex Inc.), 
which provided sufficient component resolution and sensitivity for measurement of inosine 
and hypoxanthine in human plasma samples, from healthy volunteers and emergency 
department patients presenting with chest pain with and without acute cardiac ischemia. 
4.2 Human Plasma and Serum Sample Procurement 
 
 To obtain human plasma samples used for analytical evaluations (HPLC-UV and 
Luminometer), approvals from Virginia Commonwealth University (VCU) Institutional 
Review Board (IRB) (Appendix C) and Chippenham Hospital (Richmond, VA) Clinical 
Chemistry Department were obtained.  Plasma samples (lithium heparin) from normal 
healthy individuals (non-symptomatic for cardiac disease) were acquired from VCU 
Medical Center and plasma samples (lithium heparin) from non-traumatic chest pain 
patients were acquired from Chippenham Hospital Clinical Chemistry Department.  All 
obtained samples were frozen (-20°C or below) after draw and prior to analysis. 
In addition, purchased human plasma (EDTA and lithium heparin anticoagulant) 
from cardiac diseased patients (e.g. hypertension, acute myocardial infarction), human 
blank plasma (lithium heparin anticoagulant) and serum samples (SST and non-SST) were 
commercially obtained from a FDA certified biorepository, ProMedDx (Norton, MA, 
USA) (Appendix D), which utilized an IRB protocol for their sample procurements.  The 
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ProMedDx samples were stored frozen (-20°C or below) after draw and during storage 
prior to analytical evaluations. 
 
4.3 HPLC-UV Assay Development 
4.3.1 Experimental 
4.3.1.1 Chemicals and Blank Plasma 
 Hypoxanthine and xanthine were purchased from Acros Organics (Fair Lawn, NJ, 
USA) and adenosine, inosine and uric acid were purchased from Sigma-Aldrich (St. Louis, 
MO, USA) with all chemicals being ACS reagent grade or higher purity.  For mobile phase 
preparation, trifluoroacetic acid (TFA) was reagent grade, methanol was Optima HPLC 
grade and both were purchased from Fisher Scientific (Fair Lawn, NJ, USA).  Ultrapure 
distilled and deionized water (18 MΩ-cm) used for all HPLC work was prepared in-house 
using PureLab® Ultra water purification system (US Filter, Lowell, MA, USA) and 0.2 µm 
filtered prior to use.  Blood bank human blank plasma (acid citrate) used for preparation of 
controls was provided by VCU Medical Center, Richmond, VA USA. 
4.3.1.2 HPLC Equipment and Mobile Phase 
 
The HPLC-DAD (diode array detector) equipment consisted of a Hewlett Packard 
(HP) Model 1090 HPLC system (Agilent Technologies, Palo Alto, CA, USA).  The 
analytical column used was a Phenomenex® Onyx™ monolithic C18, 20 cm x 4.6 mm I.D., 
130 Å column coupled to an Onyx™ C18 guard column, 5 cm x 4.6 mm I.D. (Torrance CA, 
USA).  The guard column was replaced after each analytical run of approximately 50 
samples.  The mobile phase consisted of aqueous trifluoroacetic acid (0.1% TFA in 
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deionized water, pH 2.2, v/v) and methanol gradient.  The mobile phase gradient was 
programmed with time course as follows (99:1 0.1% TFA in deionized water:methanol, 
v/v at 0 min and held for 3 min; 70:20 0.1% TFA in deionized water:methanol, v/v at 10 
min; 5:90 0.1% TFA in deionized water:methanol, v/v at 11 min and held 2 min, and 99:1 
0.1% TFA in deionized water:methanol, v/v at 14 min). 
The mobile phase was continuously degassed using helium sparging and used at a 
flow-rate of 1.0 ml/min.  Typical HPLC operating pressure at gradient time 0 min 
conditions was approximately 84 bar with ambient column temperature.  An injection 
volume of 15 µl of the prepared plasma sample was accomplished using the HP Model 
1090 autosampler.  Component detection was achieved using the HP Model 1090 DAD 
detector with data collection at the optimal UV wavelength absorption of 250 nm for both 
inosine and hypoxanthine.  The detector was operated at high sensitivity set point with a 1 
s response time.  A 345 kPa back-pressure regulator (SSI, State College, PA, USA) was 
coupled to the detector outlet to prevent mobile phase out-gassing.  Data acquisition and 
component computations were performed using TotalChrom™ Workstation software 
(Perkin Elmer™, Norwalk, CT, USA). 
4.3.1.3 Standard and Control Preparation, Freeze-Thaw Study 
Stock standards of adenosine (374.2 µM), inosine (372.8 µM), hypoxanthine (734.7 
µM), xanthine (657.4 µM) and uric acid (594.8 µM) were prepared in deionized water and 
stored at 4°C.  Working standards to establish HPLC retention times of adenosine (9.4 
µM), xanthine (16.4 µM) and uric acid (14.9 µM) components were prepared in deionized 
water.  Working standards of inosine (0.9, 1.9, 3.7, 11.2 and 18.6 µM) and hypoxanthine 
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(1.8, 3.7, 7.3, 22.0 and 36.7 µM) were prepared in deionized water.  All working standards 
were stored at -70°C and stable for at least 6 months.  Working controls of inosine (0.9, 7.5 
and 14.9 µM) and hypoxanthine (1.8, 14.7 and 29.4 µM) were prepared using pooled 
hospital blood bank blank plasma (n=3 donated lots) which were evaluated individually 
and confirmed to lack detectable levels of inosine and hypoxanthine components. 
It is possible the levels of inosine and hypoxanthine in blood bank plasma were not 
detectable due to the time (>10 days) the plasma was stored refrigerated (4°C) prior to 
expiration and availability for laboratory experimental use.  Without freezing the plasma or 
utilizing plasma enzyme inhibitors, xanthine oxidase and purine nucleoside phosphorylase 
found in plasma may metabolize the normally low levels of inosine and hypoxanthine to 
their end product uric acid.  Following preparation of control samples, they were 
immediately frozen at -70°C, to prevent endogenous plasma purine nucleoside 
phosphoryase from converting inosine to hypoxanthine prior to formal sample analysis. 
To demonstrate inosine and hypoxanthine freeze-thaw stability, control samples at 
each concentration were freeze-thawed (n=2 times) and evaluated by HPLC for 
degradation.  The lack of inosine and hypoxanthine degradation from freeze-thaw from 
-70˚C was demonstrated by inosine and hypoxanthine concentrations being consistent 
(<6.0% error) with the results from the accuracy and precision evaluation (Table 8). 
4.3.1.4 Sample Conditions 
 Following hospital approval, blood was obtained from hospital emergency room 
patients (n=20), in vacutainer™ tubes containing plasma (lithium heparin) as per hospital 
emergency room protocols for patients presenting with non-traumatic chest pain and 
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potential MI or acute myocardial ischemia.  Sample tubes were centrifuged at ~1000 g for 
10 min with plasma drawn off and split into tubes for hospital clinical testing and one tube 
immediately frozen at -20°C (transferred to -70°C for storage) for inosine and 
hypoxanthine analysis.  Plasma (lithium heparin) samples from healthy blood donors (male 
and female, both genders >18 years of age) were purchased from ProMedDx (Norton, MA, 
USA) which used an IRB approved specimen collection protocol and stored frozen at -
70°C.  Prior to HPLC analysis, plasma samples were thawed to ambient temperature, 
mixed thoroughly by inversion and centrifuged at 1000 g for 10 min to eliminate fibrous 
material. 
4.3.1.5 Sample Preparation 
Samples were prepared for HPLC analysis by pipetting 250 μl of plasma into a 
polypropylene Microcon® YM-10 (10,000 molecular weight cutoff, MWCO) centrifugal 
filter tube (Millipore, Bedford MA, USA).  The sample tubes were capped and centrifuged 
at 14,000 g for 15 min at ambient lab temperature.  The clear filtrates were transferred to 
deactivated glass HPLC autosampler vials (Waters®, Milford MA, USA) with 15 μl 
injected into the HPLC system for analysis. 
4.3.2 Results and Discussion 
4.3.2.1 HPLC Conditions Optimizations 
Several types of C18 columns were evaluated for resolving adenosine, inosine, 
hypoxanthine, xanthine and uric acid from other plasma components.  Due to minimal 
sample preparation using the centrifugal membrane filter, the ideal HPLC column should 
have high efficiency for resolving inosine and hypoxanthine components from components 
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in the plasma matrix.  Conventional HPLC columns such as Synergi Polar-RP C18 (15 cm 
x 3.0 mm ID x 4 µm packing) and Hypersil ODS C18 (15 cm x 3.2 mm ID x 3 µm packing) 
were evaluated versus the recently marketed HPLC column technology, the Onyx 
monolithic C18 column (10 cm x 4.6 mm ID). 
The monolithic column provided superior chromatographic resolution of 
components as described later in section 4.3.2.4 with a low system backpressure of 
approximately 84 bar (gradient time zero conditions and flow rate of 1 ml/min).  It should 
be emphasized that both conventional HPLC columns were evaluated at operating flow 
rates of ~0.6 ml/min and with system pressures that were approximately twice as high as 
when using the monolithic column.  The supplier of the monolithic column cited 
advantages of high component efficiencies (resolution) and low system backpressure with 
use of the new monolithic column technology.  We observed that both of these stated 
advantages over the two conventional mid-bore diameter HPLC columns evaluated were 
clearly demonstrated.  The mobile phase aqueous component, 0.1% TFA in deionized 
water, provided a pH of 2.2 which also provided good peak shape (e.g. uric acid 
component, pKa ~5.8) from components of interest from the endogenous plasma 
components (MW <10,000 Da) obtained from the YM-10 sample preparation. 
Optimization and adjustment of the acid strength improved the separation between 
hypoxanthine (RT 5.2 min) and uric acid (RT 5.7 min). Initial use of aqueous 0.05% TFA 
did not provide component baseline resolution while aqueous 0.1% TFA offered complete 
component baseline resolution at the expense of increased column retention times.  The 
mobile phase organic modifiers (e.g. acetonitrile versus methanol) were evaluated to 
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determine which organic solvent would provide the best chromatographic separation from 
endogenous plasma components and at the same time being most cost effective.  Methanol 
was chosen as the organic modifier as it provided symmetrical component peak shapes and 
good selectivity from other endogenous plasma components; however the HPLC system 
backpressure was somewhat higher when using methanol with the methanol gradient 
increasing from 1 to 90%.  Methanol is also more cost effective for routine HPLC analysis 
because of its lower procurement cost. 
A mobile phase gradient was used for reproducible separations of the structurally 
similar purines (hypoxanthine, uric acid) and nucleosides (inosine, adenosine).  Since the 
mobile phase organic constituent is critical to controlling component elution times (initial 
1% methanol composition at gradient time zero), the use of protein precipitation technique 
using solvents such as acetonitrile or methanol (typically 1:1 or 2:1, organic:plasma ratio) 
was eliminated from consideration..  The structurally similar components injected using 
organic solvent precipitation were not chromatographically resolved due to band 
broadening effects from the added organic modifier.  Different column oven temperatures 
(e.g. ambient lab of 20°C, 30°C and 40°C) were evaluated without significant 
chromatographic improvement (component resolution, peak shape), thus ambient 
temperature was utilized for the analysis.  At higher column temperatures (e.g. 40°C), 
component co-elution for both early (hypoxanthine, uric acid) and late components 
(inosine, adenosine) was observed. 
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4.3.2.2 Linearity, Limits of Quantitation and Detection, Computations 
The plasma method was linear throughout the concentration range of 0.9 to 18.6 
µM for inosine (mean correlation coefficient of 0.9991, n=10) and 1.8 to 36.7 µM 
hypoxanthine (mean correlation coefficient of 0.9998, n=10) with all standard back-
calculated values within 5% of their nominal amount.  The limit of detection (LOD) for 
inosine (0.4 µM) and hypoxanthine (0.7 µM) was determined using a fortified amount of 
each component in pooled blood blank plasma (n=3 each) and calculation from each 
component’s standard curve (component peak heights had greater than 3 times s/n than 
blank plasma background).  For plasma component calculations and reporting results, 
normal linear regression utilizing external standardization and peak height was used with 
the lowest calibration standard as the limit of quantification (defined as combined accuracy 
and precision within 20% of the nominal amount). 
4.3.2.3 Accuracy, Precision and Recovery 
The accuracy and precision for the method was determined by evaluation of 
replicate prepared plasma control samples (inosine at 0.9, 7.5, 14.9 µM and hypoxanthine 
at 1.8, 14.7, and 29.4 µM) (Table 8).  The combined intra-day (within day) and inter-day 
(between day) accuracy of the method was reported as the percent error of nominal 
fortified amounts versus measured component concentrations.  The combined intra-day 
and inter-day precision of the method was reported as percent relative standard deviation 
(% RSD).  The method demonstrated sufficient accuracy (±6%) and precision (±8.1) for 
both components in plasma (n=15 at each component concentration level).  Absolute 
recovery for the plasma method was evaluated by comparing the extracted fortified control 
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Table 8 
Combined intra and inter-day accuracy and precision for inosine and hypoxanthine in 
plasma controls.  Controls demonstrated excellent accuracy ±6% and precision ±8.1% 
throughout the plasma concentration range. 
 
 
Component 
Fortified 
Concentration (µM) 
n=15 
Calculated Mean 
Concentration (µM) 
n=15 
 
% Error 
 
% RSD 
Inosine 0.93 0.91 -2.8 8.1 
Inosine 7.5 7.3 -1.7 4.9 
Inosine 14.9 14.6 -2.2 3.6 
Hypoxanthine 1.84 1.95 6.0 7.5 
Hypoxanthine 14.7 15.0 2.2 5.5 
Hypoxanthine 29.4 28.9 -1.7 2.2 
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samples prepared in pooled blood blank plasma versus unextracted standards prepared in 
deionized water (n=3).  The absolute recovery for the plasma method was determined to be 
>98% for both inosine and hypoxanthine.  In addition, the standards and controls used for 
all HPLC analysis were prepared and handled identical to patient and volunteer subject 
samples, thus controlling for potential errors in sample handling, micropipetting and YM-
10 component extraction recovery. 
4.3.2.4 Chromatography 
Figure 14 illustrates chromatograms of 14.7 µM hypoxanthine (RT ~5.3 min), 11.9 
µM uric acid (RT ~5.8 min), 13.1 µM xanthine (RT ~7.2 min), 7.5 µM adenosine (RT 
~10.7 min) and 7.5 µM inosine.  patient. (RT ~10.9 min) in deionized water for marking 
component retention times; limit of quantitation and lowest plasma standard of 1.84 µM 
hypoxanthine and 0.93 µM inosine; pooled blank plasma (acid citrate) from the VCU 
Health Systems Hospital blood bank; prepared plasma (lithium heparin) from a healthy 
female subject; and prepared plasma (lithium) from a hospital emergency room female 
patient exhibiting symptoms of chest pain and acute myocardial ischemia (Figures A, B, C, 
D and E, respectively). 
The method demonstrated good component chromatographic selectivity with no 
endogenous plasma interferences at the retention times of hypoxanthine and inosine.  This 
method also provided sufficient sensitivity for both components of interest using 
conventional UV detection with an analytical run time of ~21 min (allows mobile phase 
gradient equilibration).  To extend column lifetime, the analytical column was flushed after 
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Figure 14. Chromatograms illustrating (a) 14.7 µM hypoxanthine (RT ~5.3 min), 11.9 µM 
uric acid (RT ~5.8 min), 13.1 µM xanthine (RT ~7.2 min), 7.5 µM adenosine (RT ~10.7 
min) and 7.5 µM inosine (RT ~10.9 min) in deionized water, (b) low standard of 1.84 µM 
hypoxanthine and 0.93 µM inosine in blank plasma, (c) blank plasma, (d) plasma sample 
from healthy female subject and (e) plasma sample from hospital emergency room female 
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E 
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each analytical run (~50 injections) for 1 h at 1.0 ml/min with acetonitrile: deionized water 
(90:10, v/v) to eliminate potential retained non-polar substances from the column. 
4.3.2.5 Sample Preparation Optimization and Filtrate Stability 
Sample preparation evaluations using protein precipitation and centrifugal 
membrane filters were conducted.  As previously described in Section 4.3.2.1, organic 
solvent precipitation was not useful due to resulting poor chromatographic resolution of 
structurally similar components.  TCA (trichloroacetic acid) was not evaluated due to the 
hazards of using the strong acid and the resulting sample dilution effect potentially 
affecting overall method sensitivity.  The centrifugal membrane filter is commonly used to 
concentrate peptides, proteins and nucleic acids for proteonomic and genomic 
determinations [Microcon Centrifugal Filter Devices]. 
Since the molecular weights of our components are all less than 300 Da, our 
approach to using this technique was to inject the filtrate which would contain the low 
molecular weight components that transfers across theYM-3 or YM-10 cellulose 
membrane cutoff filters.  This essentially removes most peptides and all proteins from the 
sample to be injected as they are retained by the cellulose membrane cutoff filter, thus 
improving method selectivity.  Method sensitivity is also improved because there is no 
sample dilution effect since there is no solvent added. 
Evaluations to optimize sample preparation conditions using the YM-10 (10,000 Da 
MWCO) and YM-3 (3,000 Da MWCO) centrifugal filter were conducted.  With the 
centrifugal force set at 14,000 g (recommended by YM-10 supplier) and using 250 uL of 
prepared plasma control samples, the centrifuge spin time was varied from 5, 15, 30 and 60 
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min.  The five min spin time did not provide enough time to adequately separate plasma 
proteins from the aqueous matrix (salts, small peptides and substances less than 10,000 Da) 
with an insufficient amount of sample filtrate recovered.  The 15, 30 and 60 min 
centrifugal spin times resulted in maximum recovery of sample filtrate.  However the 60 
min spin filtrate samples were significantly warmer than ambient lab temperature most 
likely due to warming effects of the sample tubes friction with air from the centrifugal 
spin.  Thus to eliminate potential component degradation due to heat from spinning 60 min 
and to shorten sample preparation time, a spin time of 15 min was used for all analyses as 
described in section 3.3. 
Results for the YM-3 filter evaluation demonstrated longer spin times were required 
(~45 to 60 min) at 14,000 g versus the 15 min spin using the YM-10 filter.  The YM-3 
filtrate did not offer better filtration of smaller plasma peptides (<10K Da), as observed on 
chromatograms, than was already achieved using the YM-10 filter.  However, using either 
YM-3 or YM-10 filter effectively removed the purine nucleoside phosphorylase enzyme 
(nominal weight ~90-94 KDa protein, [Cook et al., 1981; Osborne, 1980]) thus eliminating 
the potential for inosine to hypoxanthine metabolism in the sample filtrate.  The filtrates 
were stored frozen (-70˚C) after HPLC analysis with both inosine and hypoxanthine 
components demonstrating stability for greater than 3 months. 
4.3.2.6 Plasma Purine Nucleoside Phosphorylase Activity 
Purine nucleoside phosphorylase (PNP, EC 2.4.2.1) is an enzyme that rapidly 
metabolizes inosine to hypoxanthine in blood (t½ <5 min due to red blood cells).  This 
enzyme has low activity in plasma and is normally found in human cardiac muscle, GI 
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tract, spleen, brain and red blood cells [Viegas et al., 2000; Yamamoto et al., 1995].  
Therefore, to better estimate an ischemic heart’s effluxed inosine during periods of acute 
cardiac oxidative stress, venous blood samples should be kept cold (ice) and prepared 
immediately.  Either the blood sample should be immediately inhibited (e.g. peldesine, 
competitive inhibitor (Viegas et al., 2000)) or the metabolite hypoxanthine should be 
simultaneously determined with inosine to better estimate the level of acute cardiac 
ischemia. 
In whole blood or plasma samples, hypoxanthine will not be further metabolized to 
xanthine as the human enzyme xanthine oxidase (XO), which is require for hypoxanthine 
to xanthine conversion, has low activity in plasma (Yamamoto et al., 1996) and is typically 
found in human tissue (liver, small intestine) and other bodily fluids (milk and colostrum).  
A plasma (heparinized) sample is recommended for inosine and hypoxanthine 
determination in that the approximate 30 min clot time required for a serum sample would 
allow significant conversion of inosine to hypoxanthine in the collection tube, which 
would contain PNP from the red blood cell and plasma matrix. 
Several evaluations (n=3 samples at each condition) were performed to evaluate 
inosine metabolism by PNP activity in plasma stored at 4˚C (refrigerator), -20˚C and 
-70˚C.  Results of the evaluation can be seen in Figure 15; plasma fortified with inosine 
only at 7.46 µM and without PNP enzyme inhibitor is metabolized rapidly to hypoxanthine 
(~70% in 24 hrs); plasma fortified with 0.93 µM of inosine and 1.84 µM hypoxanthine and 
without PNP enzyme inhibitor is also metabolized rapidly to hypoxanthine (~70% in 24 
hrs); however the plasma fortified with 7.46 µM of inosine and 14.69 µM hypoxanthine 
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Figure 15. Graph of mean percent inosine remaining after plasma PNP metabolism when 
stored at 4˚C.  Square symbols represent fortified amounts of 7.46 µM inosine and 
14.69 µM hypoxanthine in blank plasma (n=3), diamond symbols represent fortified 
amounts of 0.93 µM inosine and 1.84 µM hypoxanthine in blank plasma (n=3), and 
triangle symbols represent fortified amount of 7.46 µM inosine only in blank plasma 
(n=3). 
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and without a PNP enzyme inhibitor, is metabolized less rapidly to hypoxanthine (~30% in 
24 hrs) and slightly less than 50% after 72 hrs.  Results of storing fortified plasma samples 
at -20˚C immediately after preparation indicated a reduced rate of inosine to hypoxanthine 
conversion (~30% after 8 months) with storage at -70˚C almost completely deactivating 
the PNP enzyme (<5% inosine conversion after 3 months).  A possible explanation for the 
plasma hypoxanthine-concentration dependence for the conversion rate of inosine to 
hypoxanthine, would be product inhibition (PNP Keq≈0.04 mM) (Brenda Enzyme 
Database).  This low Keq indicates that thermodynamically, inosine synthesis is favored 
over product conversion to hypoxanthine. 
When the venous sample plasma concentration of hypoxanthine is present at higher 
levels (e.g. 14.69 µM), the conversion of inosine to hypoxanthine by plasma PNP 
decreases in the absence of significant XO enzyme activity, which converts hypoxanthine 
to xanthine and uric acid for biological elimination (therefore XO activity ultimately 
increases PNP activity as it reduces hypoxanthine product inhibition of PNP).  It was also 
determined that the total amount of inosine and hypoxanthine fortified into the pooled 
plasma was recovered, thus verifying the lack of significant XO activity in human plasma 
and supports our recommendation of simultaneous determination of both inosine and 
hypoxanthine components. 
A preliminary investigation to show the utility of the method is shown in Figures 
14D (healthy control with 1.3 µM inosine and 2.74 µM hypoxanthine) and 14E (acute 
cardiac ischemia patient with 2.39 µM inosine and 29.3 µM hypoxanthine).  These figures 
demonstrate an increase in both inosine and hypoxanthine concentrations (as well as final 
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ATP catabolic by-product uric acid) in one patient having presented with non-traumatic 
chest pain and undergoing evaluation for acute cardiac ischemia.  Figure 16 demonstrates 
significant levels (P<0.05) of inosine, hypoxanthine and a combined total inosine plus 
hypoxanthine concentration level in plasma from ED non-traumatic chest pain patients and 
healthy normal controls. 
It is important to discuss the time course of the ED patient’s blood sample draw.  
These patients arrive at the hospital emergency department with the chief complaint of 
non-traumatic chest pain.  Each patient’s time of the non-traumatic chest pain may vary 
(minutes to hours) depending on the severity of their chest pain.  Although the plasma 
samples from the ED that were evaluated for this research represent each patient’s first 
blood sample drawn for standard hospital clinical chemistry analysis (e.g. troponin I, CK-
MB), the samples themselves represent a range of time (minutes to hours) of potential 
patient acute cardiac ischemia.  Therefore, the interpretation of these ED results may have 
this as a potential confounding factor or limitation. 
4.4 Human Plasma (Heparin) versus Serum (SST) Sample Evaluation 
 Using the validated HPLC-UV method as described in Section 4.3, an evaluation 
was performed on commercially purchased human plasma (heparin) and serum (SST) 
samples.  There are many techniques used for the specimen collection of biological fluids 
(e.g. blood component).  Examples are collection of plasma, serum or serum using an inert 
gel barrier (SST) etc.  As reproducibility of test results is a critical method validation 
parameter, it becomes important to determine the proper specimen matrix for analysis and 
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Figure 16. Chart depicting inosine, hypoxanthine, and total inosine plus hypoxanthine 
concentrations (mean + SEM) in plasma from ED non-traumatic chest pain patients and 
healthy normal individuals. 
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to determine if the sample collection matrix affects the component(s) of interest (e.g. 
resulting in artifacts in component concentrations) (Magee, 2005). 
For this research, plasma (lithium) was initially selected for evaluation as many US 
hospitals typically use plasma for measurement of cTnI and CK-MB analysis (e.g. 
Chippenham Hospital).  Serum (SST) is also being evaluated to investigate why one past 
research group (Kock et al., 1994) reported hypoxanthine levels which were not 
statistically significant in their patients that were undergoing acute myocardial infarction 
and other ischemic diseases.  As this research reports elevated levels of inosine and 
significant levels of hypoxanthine in plasma from non-traumatic chest pain patients from a 
local hospital emergency department, it is important to determine and explain how the 
differences in reported hypoxanthine concentrations exist (if possible) between Kock et al. 
and this research since we evaluated similar type of patients (e.g. acute cardiac ischemia). 
Studies on sample collection matrices effects have been performed by other 
investigators with reported differences in analyte levels based on the sample matrix 
(Doumas, 1989), thereby necessitating this matrix effect study.  Samples were acquired 
from normal healthy volunteers (n=6) from a local blood bank (contracted with ProMedDx 
for this sample requirement), with each subject’s blood acquisition being obtained 
sequentially (first serum SST vacutainer sample draw followed by heparin vacutainer 
sample draw), to minimize potential inosine and hypoxanthine concentration level changes 
with time and phlebotomy techniques.  When drawing multiple sample types from the 
same subject, sample order of draw is documented as red top (serum) prior to green top 
(heparin) to prevent potential anti-coagulant (heparin) contamination in the serum sample 
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(ABP, Inc. 2004).  Per ProMedDx, all collected samples were processed and handled 
according to BD Vacutainer® inserts (e.g. centrifugation at 1200 g for 15 min) (BD 
Vacutainer®, 2007), with the serum SST sample taken first followed by the heparin sample 
(prevents potential anticoagulant carryover effect). 
As some biomarkers are diurnal and time sensitive (e.g. some endogenous 
hormones and proteins (e.g. CRP)), it supports the importance of requiring sequential 
samples for this small study to eliminate potential errors, as inosine and hypoxanthine are 
also endogenous to plasma and may possibly fluctuate throughout the day.  After thawing 
samples to ambient temperature, each was prepared using the 30K centrifugal membrane 
filter and micro-centrifuged at 14,000 x g for 5 min, with all preparations analyzed by 
HPLC (single injection of each sample) on the same analytical run date. 
As demonstrated in Figure 17, there were differences observed in the hypoxanthine 
concentrations from the same subject, with the serum (SST) samples generally higher in 
hypoxanthine concentrations.  A possible reason for observing the higher hypoxanthine 
levels when using serum (SST) can be caused by red blood cell hemolysis during 
preparation.  It is also known that hemolysis is a common occurrence when using serum 
samples (Arzoumanian, 2003) with another published article reporting significant 
differences between 10 of 17 plasma and serum measured analytes (Hrubec et al., 2002). 
When using the SST tube for collection, the BD package insert directions state to 
gently invert the tube 5 times and let the tube sit 30 min prior to centrifugation.  During 
this time period, the blood clots (as no anticoagulant is used) with a formed thrombus.  
With centrifugation, the formed thrombus remains near the bottom of the tube with the 
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Figure 17.  Bar chart depicting differences in hypoxanthine concentrations between plasma 
(lithium heparin) and serum (SST) from normal healthy individuals.  Overall, SST samples 
demonstrated ~19% positive bias relative to the plasma (lithium heparin) samples. 
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other matrix components migrating upwards and around the inert gel (found initially at the 
bottom of the tube but migrates upwards based on material density). 
It is feasible that during this clotting time and subsequent centrifugation step, that 
some red blood cells may leak some of its contents or hemolyze (rupture) due to 
mechanical deformation, which has been recently reported with RBC (Sprague et al., 2001, 
Sprague et al., 1996).  It has also been reported that inside red blood cells, ATP is typically 
found in significant amounts (mM levels) as the RBC also functions as an ATP storage 
vesicle (Dietrich et al., 2000).  If ATP is released from the RBC into the blood sample 
matrix, it is enzymatically converted several times to form hypoxanthine (Heptinstall et al., 
2005, Coade et al., 1989), which may cause falsely elevated hypoxanthine results (artifact). 
4.5 Other Cardiovascular Disease Matched Sample Set Evaluations 
 Further investigations into the effect of sample matrix were performed using 
additional commercially purchased matched sample sets (contract with ProMedDx for 
n=10 matched sets for each requested sample group).  For this study, additional normal 
healthy (non-symptomatic for ischemic cardiac disease) individual samples of plasma 
(heparin) and serum (no gel) were collected and frozen at -20°C.  The results of these 
additional normal individuals can be used for comparison to the results obtained in Section 
4.4 (i.e. healthy normals serum with gel (SST) versus healthy normals serum without gel). 
In addition, matched sample sets representing two cardiovascular disease states 
(e.g. hypertension, acute myocardial infarction) were also purchased from ProMedDx for 
evaluation to determine patient basal concentrations of inosine and hypoxanthine in these 
two cardiovascular disease states; however these matched sample sets were only available 
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in plasma (heparin) and serum (SST).  The plasma (lithium) and serum (SST) samples 
from hypertension and acute myocardial infarction patients were collected at a hospital in 
contractual agreement with ProMedDx with serum (SST) being the hospital normal sample 
protocol for collecting serum samples and the collected samples frozen at -20°C prior to 
HPLC-UV analysis.  Clinical diagnosis and demographic information (e.g. age, gender, 
medications) on patients with hypertension and acute myocardial infarction were provided 
by the hospital where the matched sample sets were obtained. 
Appendix D list the sample sets and HPLC-UV results for this section.  Several 
observations can be seen from the results.  The matched sets for normal healthy individuals 
had similar plasma and serum (without the inert gel, not SST) concentrations for inosine 
and hypoxanthine.  These results suggest that the initial results from using serum (SST) 
from normal healthy individuals may have gel contributed artifacts affecting the 
component concentrations (more notably hypoxanthine).  In addition, the matched set 
samples from hypertension and acute myocardial infarction had notable differences in 
plasma and serum (SST) concentrations, somewhat for inosine but mainly for 
hypoxanthine (mostly higher hypoxanthine results, but with some variable results in the 
acute myocardial infarction samples).  However, it is important to note that the hospital 
patient samples may also have medications which contribute to the observed phenomena. 
Based on these studies, it should be recommended that plasma (lithium heparin) be 
used as the sample collection matrix for the analysis of human hypoxanthine and inosine.  
While serum (without gel) appears to be an acceptable matrix, it does require waiting for 
30 min for the blood to clot prior to centrifugation, thereby adding to the total time from 
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patient sampling to analytical results to be returned from the clinical laboratory to the 
emergency room physician. 
The HPLC results from blood samples collected using different vacuutainer 
additives (e.g. lithium heparin, SST) may help to explain differences in hypoxanthine 
concentrations from the Kock et al. study (1994 article) and this research work.  Kock et al. 
reported no significant differences in hypoxanthine concentrations from their study 
patients (e.g. acute MI patients versus healthy controls), whereas this research reports 
significant differences from ED non-traumatic chest pain patients versus healthy normal 
individuals.  Two possible reasons may account for the reported differences in 
hypoxanthine concentrations. 
Firstly, the Koch et al. group used SST collection tubes and this study used lithium 
heparin for collecting plasma; thus the blood collection additives were different.  Secondly, 
Koch et al. did not use ED non-traumatic chest pain patients (non acute MI when the blood 
sample was drawn) for their study as were used in this research work.  Since there are no 
published kinetic studies of hypoxanthine in blood from non-traumatic chest pain or acute 
myocardial infarction patients, it is possible that the concentrations of hypoxanthine in the 
blood may be very different in these two groups of cardiac patients (e.g. patient chest pain 
is a typical symptomatic event preceding an acute myocardial infarction). 
When collecting blood from an individual, the choice of blood collection additives 
can be just as important as the analytical test method.  For this research, the differences 
between collecting plasma (lithium heparin) and SST from whole blood demonstrated 
variable hypoxanthine concentrations (artifacts).  For example, in Figure 17, a consistent 
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positive bias in hypoxanthine concentrations from SST samples relative to lithium heparin 
plasma samples from normal healthy individuals (called matched sets) was demonstrated.  
However variable hypoxanthine concentrations were observed in patients with heart 
disease conditions (e.g. PromedDx lithium heparin plasma and SST matched set samples 
representing hypertension (HT) and acute myocardial infarction (cTnI) patients are listed 
in Appendix D), which indicates that hypoxanthine concentration artifacts may occur if 
using SST collection tubes for hypoxanthine analysis. 
Thus, in order to obtain reproducible inter-laboratory hypoxanthine concentration 
results, lithium heparin should be used as the additive and not serum (SST), as the SST gel 
appears to cause spurious artifacts.  Artifacts using SST gels are not unique, as several 
other investigators have reported similar findings when using serum (SST) for their studies 
(e.g. progesterone, (Ferry et al., 1999); free triiodothyronine (FT3), Kilinc et al., 2002). 
4.6 Conclusion 
A sensitive and selective method has been developed for evaluation of inosine and 
hypoxanthine in human plasma.  The method employed a one step sample preparation for 
plasma (no organic solvents or solid phase extraction cartridges required) with high analyte 
recoveries, which eliminated the need for an internal standard.  In addition, this method 
utilized recently introduced HPLC monolithic column technology, which provided 
sufficient selectivity and sensitivity for measurement of these components.  Subject 
matched set sample evaluation indicated a consistent positive bias in hypoxanthine levels 
from use of SST collection tubes relative to plasma (heparin), thus the recommendation of 
using plasma (heparin) collection to eliminate any potential artifacts and reduce total 
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analysis time (serum and SST samples require ~30 min clotting time prior to 
centrifugation).  The method was employed without significant methodological problems 
in the evaluation of plasma samples obtained from healthy individuals and hospital 
emergency department patients presenting with non-traumatic chest pain with significant 
levels of both inosine and hypoxanthine effluxed from the patient samples.  These results, 
albeit from a small sample size (n=20 each group), further support the research hypothesis 
that these components may qualify as potential candidate biomarkers of acute cardiac 
ischemia. 
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CHAPTER 5. Rapid Chemiluminescence Detection of Inosine and 
Hypoxanthine using Microplate Luminometer 
 
 
 
5.1 Introduction 
The goal of this chapter of research is the development of a rapid chemi-
luminescence test method for determination of inosine and hypoxanthine in human plasma.  
The purpose is to allow for rapid patient screening capability (diagnostic tool for acute 
cardiac ischemia) for potential use in hospital emergency department environments.  The 
luminescence method will be utilized on samples from healthy individuals and hospital 
patients with confirmed acute MI (hospital documented elevated levels of cTnT).  To be 
effective, the method will need to be rapid (defined as less than 10 min analysis time), 
sensitive and specific for inosine and hypoxanthine to reduce the potential errors in 
interpreting sample test results (e.g. goal is to minimize false positive and false negative 
results). 
 Currently, there are no published articles or U.S. patents for a rapid test method to 
determine inosine and hypoxanthine in plasma, which can meet the stringent sample 
turnaround time requirements of an emergency medical services (EMS) environment.  The 
rationale for using chemiluminescence technology over commonly used LC and 
immunoassay technologies are as follows:  LC and immunoassay methods are both very 
sensitive and specific techniques (e.g. monoclonal antibodies for immunoassay and mass 
spectrometer detection for LC); however, an LC-MS system is expensive to purchase and 
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operate, both techniques require technical expertise to perform, and both lack a rapid 
enough turnaround time needed by an EMS facility analyzing a priority “stat” type sample.  
However, a luminometer can measure chemiluminescent light, is relatively inexpensive to 
purchase, currently used in clinical labs (microplate capability), and can provide high 
component sensitivity. 
 Luminescence technology is well established with many instrument vendors (e.g. 
BMG LabTech Inc. Lumistar Optima (Durham, NC, USA), BioTek Synergy HT 
(Winooski, Vermont, USA), Thermo Fisher Scientific Luminoskan (Waltham, MA, USA)) 
and suppliers (e.g. Corning Life Sciences, Lowell, MA, USA) of luminescence supplies 
and reagents available worldwide.  It is known to be one of the most sensitive techniques, 
with one recent publication on its application for low ng/ml concentrations of ATP in 
human plasma [Gorman et al., 2007].  The high sensitivity of luminescence is primarily 
due to its high analyte signal to noise (s/n) ratio, with reported detection levels at low 
picogram and femtogram levels. 
To address biomarker specificity requirement, the developed luminescence test 
method will utilize biological enzymes purine nucleoside phosphorylase (PNP) and 
xanthine oxidase (XO), which are specific for enzymatic conversions of inosine and 
hypoxanthine, respectively.  The PNP enzyme converts inosine to hypoxanthine and XO 
converts hypoxanthine to xanthine, followed by XO conversion of xanthine to final 
product uric acid (in human species).  Each time XO reacts with one mole of 
hypoxanthine, and subsequently with one mole of xanthine, the metabolic by-products of 
each XO enzymatic turnover is the production of one mole of hydrogen peroxide and two 
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moles of superoxide anion radical (O2-·), which both of these by-products can become 
substrates for luminescence type reactions.  Several commonly used luminescent materials 
(e.g. luminol (oxidation), lucigenin (reduction), and pholasin (oxidation)) were considered 
for this research.  If using luminol or lucigenin as the luminescent material, the hydrogen 
peroxide (which has both oxidizing and reducing capabilities) can react with the 
horseradish peroxidase (HRP) enzyme, luminol, and signal enhancers to generate 
measurable blue light ~ 450 nm, thus an amplification of signal effect (one mole of 
hypoxanthine and xanthine can generate two moles of hydrogen peroxide) (Figure 18). 
However, to achieve even greater sensitivity as low concentration (ng/ml or µM) 
levels of inosine and hypoxanthine are typically found in human plasma, another 
luminescence approach was investigated, which utilizes a highly sensitive photoprotein 
(pholasin®).  Since one mole of hypoxanthine will generate 4 moles of superoxide anion 
radicals (SAR) as a by-product of XO activity, using a chemiluminescent material that 
reacts with SAR should theoretically provide even more luminescence signal, thus 
potentially increasing the sensitivity twice fold over using the hydrogen 
peroxide/horseradish peroxidase/luminol approach.  One article cited pholasin having more 
than 100 fold sensitivity than lucigenin (Knight, 1997). 
Pholasin®, a photoprotein isolated from the bi-valve mollusk, has been reported to 
be a very sensitive chemiluminescent material (called lucidalin®) for SAR and other 
reactive oxygen species (ROS) such as the hydroxyl free radical (Knight, 1988).  Pholasin® 
has been extensively studied and patented by Knight Scientific, Plymouth, UK.  It is an 
approximately 34-36 kDa glycoprotein, which can be made excitable by several ROS,  
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Figure 18.  Diagram of enzymatic conversions of inosine and hypoxanthine components 
with generation of hydrogen peroxide as a by-product, which can react with luminol or 
lucigenin and HRP to generate visible blue light (chemiluminescence). 
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emitting blue-green light, and it has been reported to not have fluorescent properties.  The 
presence of SAR can react with the pholasin photoprotein to generate measurable light 
(~490 nm) (Figure 20), thus an amplification of signal effect (one mole of hypoxanthine 
can generate four moles of SAR), which should increase sensitivity and provide lower 
component detection limits.  The reaction of pholasin with SAR can be very quick (flash 
type technique, typically seconds) and may be made even more sensitive with use of signal 
enhancers (e.g. Adjuvant-k (proprietary) from Knight Scientific). 
 The Lumistar Optima Microplate Reader (BMG LabTech, Durham, NC, USA) was 
used for all luminescence evaluations.  The instrument has temperature control, supports 
the use of 96 well plates (opaque white) which were purchased from Corning Life Sciences 
(Lowell, MA, USA), and is capable of variable microplate mixing speeds with flash and 
glow luminescence capabilities.  The instrument is fitted with two direct injectors capable 
of rapid injections (e.g. 310 ul/sec), thus micropipetting assay reagents into the sample 
wells was automatically performed, which may help to reduce potential errors from manual 
pipetting. 
5.2 Experimental 
5.2.1 Chemicals, Reagents and Materials 
 Hypoxanthine, xanthine and ethyl alcohol (HPLC grade, denatured) were 
purchased from Acros Organics (Fair Lawn, NJ, USA).  Inosine, dibasic sodium hydrogen 
phosphate, and uric acid were purchased from Sigma-Aldrich (St. Louis, MO, USA).  
Enzymes xanthine oxidase (isolated from bovine milk, Grade III, ammonium sulfate 
suspension, enzymatic activity ~1.3 units/mg protein, storage temp 2-8°C), 
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Figure 20.  Diagram of typical reagent addition, injector time points and resulting pholasin 
emission (chemiluminescence). 
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purine nucleoside phosphorylase (isolated from human blood, lyophilized powder, 
enzymatic activity ~19 units/mg protein., storage -20°C) and uricase (isolated from 
Arthrobacter globiformis, lyophilized powder, ~19.7 units/mg protein, storage -20°C) were 
all purchased from Sigma-Aldrich. 
A commercial test kit used for antioxidant evaluations was purchased for initial 
setup of the luminometer and included an assay utilizing xanthine/xanthine oxidase plate 
mode kinetics (glow technique).  The kit included pholasin (50 µg), xanthine, xanthine 
oxidase [~10.25 mU/ml] and buffer (proprietary) for plate mode kinetics and was 
purchased from Knight Scientific (Plymouth, UK).  The luminometer instrument was 
qualified using the commercial antioxidant test kit and by successful replication of the 
xanthine/xanthine oxidase plate mode kinetics profile from Knight Scientific.  For all 
experiments following instrument qualification, the reagents and enzyme solutions were 
prepared accordingly.  Dibasic sodium hydrogen phosphate was used to prepare the 20 
mM assay buffer solution with ultrapure deionized water as the diluent (final pH 7.4 using 
concentrated phosphoric acid).  Ultrapure deionized water (~18 MΩ-cm) used for all 
reagent solutions was filtered (0.2 µm) prior to use. 
The luminometer rinse solution for the direct injector syringes was prepared using 
ethyl alcohol:deionized water mixture (75:25%, v/v).  Weekly rinses were performed to 
reduce potential material (e.g. protein and enzyme residue) buildup in the syringes, reagent 
tubing and injector needles.  Opaque 96 well microplates were purchased from Corning 
Life Sciences (Lowell, MA, USA) and stored in the dark at ambient temperature.  Blank 
human plasma (lithium anticoagulant) from one healthy volunteer (250 ml), an additional 
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six healthy volunteers plasma (lithium heparin) samples (1 ml each), and six patient’s 
plasma (lithium heparin) samples with confirmed acute MI (hospital reported elevated 
cTnT, 1 ml each) were purchased from ProMedDx (Norton, MA, USA) and stored at -
20°C prior to use. 
5.2.2 Preparation of Standards, Enzymes and Pholasin Solutions 
 Stock standards of inosine (25 µg/ml, 93.2 µM), hypoxanthine (25 µg/ml, 183.7 
µM), xanthine (25 µg/ml, 164.4 µM) and uric acid (25 µg/ml, 148.7 µM) were prepared in 
deionized water, stored at 4°C with stability greater than 3 months.  Working calibration 
standards for each component were prepared in deionized water immediately prior to use. 
For experiments, the working xanthine oxidase solution was prepared by pipetting 
40 µL of the aqueous stock XO (from bovine milk) suspension into 2.0 ml of assay buffer 
(pH 7.4) resulting in ~676 mU XO/ml.  The working XO solution was stable at ambient 
laboratory temperature (22°C) and could be stored at 4°C overnight with minimal loss in 
enzyme activity; however the working XO solution should not be stored frozen 
(e.g. -20°C), as a complete loss of enzyme activity was observed upon freeze-thaw and 
subsequent use. 
To prepare PNP and uricase solutions from solid and lyophilized purine nucleoside 
phosphorylase and uricase, 1.0 ml of assay buffer (pH 7.4) was pipetted directly into the 
vendor container bottle with gentle vortexing into solution.  After reconstitution using 1 ml 
of assay buffer (pH 7.4), the PNP stock concentration was ~18.7 Units PNP/ml and uricase 
stock concentration was ~110 Units uricase/ml.  A working solution of PNP [~701 mU 
PNP/ml] was prepared by pipetting 75 µL of the aqueous stock material into 2.0 ml of 
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assay buffer (pH 7.4).  A working solution of uricase [~1.1 U uricase/ml] was prepared by 
pipetting 20 µL of the aqueous stock material into 2.0 ml of assay buffer (pH 7.4).  Both 
working solutions of PNP and uricase were stable at ambient laboratory temperature and 
could be stored at 4°C overnight with minimal loss in enzyme activity. 
For preparation of the pholasin luminescent material, 5.0 ml of assay buffer (pH 
7.4) was pipetted directly into the vendor container bottle containing 50 µg pholasin with 
gentle vortexing, resulting in a ~10 µg/ml solution.  The prepared pholasin reagent was 
stable at ambient laboratory temperature and 4°C, and was stored protected from light to 
eliminate potential basal luminescence as it is an excitable photoprotein.  The reconstituted 
pholasin solution was transferred and stored in plastic screw top tubes (~1 ml aliquots 
stored at -20°C). 
5.2.3 Luminometer Equipment and Set Points 
The luminometer equipment consisted of a BMG LabTech Inc. Lumistar Optima 
and Optima software (version 2.1) (Durham, NC, USA) and Dell Optiplex 745 PC (Dell, 
TX, USA).  The luminometer was equipped with temperature control (8°C to 45°C), two 
direct injectors (minimum injection volume of 3 µl) with variable injection speeds (100 µ/s 
to 420 µ/s), and microplate shaking (orbital, linear, figure eight) capability.  The 
luminometer listed specifications for the limit of detection (<50 amol / well ATP), spectral 
range (240 – 740 nm) and dynamic range (9 decades).  All luminescence assays utilized 
opaque 96 well plates, an incubation temperature of 25°C, lens mode (no emission filter) 
and a photo-multiplier (PMT) gain setting of 3900 volts.  Equipment set points for all 
experiments in the flash mode are listed in Figure 21. 
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Figure 21.  BMG luminometer set points used for flash mode experiments. 
 135
5.2.4 Method Development and Optimization 
Development and optimization of the luminescence test method included 
evaluation of parameters such as determining hypoxanthine concentration level range, 
adjustment of XO enzyme concentration level to reduce analysis time, and enzyme 
incubation time (e.g. PNP) to maximize sensitivity and repeatability and to minimize 
turnaround time (<10 min analysis).  All plasma analysis utilized 20 µl of sample in a final 
microplate well volume of 200 µl (effectively making a 1:10 dilution of the plasma 
sample).  Potential endogenous interference (e.g. uric acid) was evaluated to determine 
quenching effects as this substance has antioxidant capacity and is typically found in 
plasma at high concentrations (e.g. 350-450 µM), especially in gout patients. 
The HPLC results from normal volunteers (ProMedDx plasma) and non-traumatic 
chest pain patients (Chippenham Hospital ED plasma) from Chapter 4 were used to 
estimate expected plasma concentrations of inosine and hypoxanthine for this chapter of 
research (Table 9).  Since the luminometer is a detection device and will not separate a 
mixture of components (as does HPLC), it was necessary to utilize the PNP enzyme and 
convert component inosine to hypoxanthine, and then measure the resulting total plasma 
hypoxanthine (inosine plus hypoxanthine) concentration.  Using the XO enzyme, 
hypoxanthine converts to xanthine, and xanthine to uric acid.  The luminometer measures 
the light signal generated from the XO reaction with hypoxanthine and xanthine (XO 
generates superoxide anion radicals which react with the luminescent material pholasin).  
Using a µg/ml to µM (micro molar) conversion table (Excel formula computations, Table 
10), a standard curve of hypoxanthine was prepared at concentration range of 
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Table 9.  Estimated inosine, hypoxanthine, xanthine and uric acid concentrations in healthy 
normal individuals and non-traumatic chest pain patients.  Values for normal individuals 
are based on published literature and the HPLC results using PromedDx healthy normal 
individuals.  Values for potential acute cardiac ischemia are from the HPLC results using 
Chippenham Emergency Department plasma (heparin) samples. 
 
Plasma Plasma
[ug/mL] [uM] Comments
Estimated lowest inosine level = 0.10 0.4
Estimated lowest hypoxanthine level = 0.10 0.7
Assume 100 % ino to hypo conv hypo = 1.1 Estimated levels (normals), n=20 from PromedDx
Estimated (normals) inosine level = 0.30 1.1
Estimated (normals) hypoxanthine level = 0.30 2.2
Assume 100 % ino to hypo conv hypo = 3.3 Estimated levels (normals) from Feng et al, Ther Drug Mon (2000) 22:177-183.
Estimated (ischemic) inosine level = 0.3 1.1 Lowest chest pain patient value
Estimated (ischemic) hypoxanthine level = 2.0 14.7
Assume 100 % ino to hypo conv hypo = 15.8 Ischemic (based on Chippenham ED data).
Estimated (ischemic) inosine level = 7.8 29.1 Highest chest pain patient value
Estimated (ischemic) hypoxanthine level = 9.7 71.3
Assume 100 % ino to hypo conv hypo = 100.3 Ischemic (based on Chippenham ED data).
Estimated (normals) xanthine level = 0.9 5.9 Estimated xanthine levels (normals) from Feng et al, Ther Drug Mon (2000) 22:177-183.
Estimated (normals) uric acid level = 60.0 356.9 Potential XO inhibitor and luminescence quenching (anti-oxidant).
Estimated (normals, high) uric acid level = 80.0 475.9 Potential XO inhibitor and luminescence quenching (anti-oxidant).
Estimated uric acid highest level (gout) = 100.0 594.8 Potential XO inhibitor and luminescence quenching (anti-oxidant).  
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Table 10.  Component µg/ml to µM conversion table. 
 
 
For Experiments Weight Volume Conc Conc  
Compound mg Ml µg/ml µM 
Adenosine 25.0 1000.0 25.0  93.6  
Inosine 25.0 1000.0 25.0  93.2  
Hypoxanthine 25.0 1000.0 25.0  183.7  
Xanthine 25.0 1000.0 25.0  164.4  
Uric Acid 25.0 1000.0 25.0  148.7  
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2.3 to 30.3 µM.  The initial hypoxanthine concentration range was set to focus on 
hypoxanthine concentrations to maximize the luminescence method sensitivity and detect 
concentration differences between healthy normal individuals and non-traumatic chest pain 
patients (e.g. ~3 µM for normal individual and ~15 µM for lowest observed chest pain 
patient).  Plasma samples above the highest standard can be diluted with deionized water.  
The initial range incorporated total inosine and hypoxanthine concentrations from both 
healthy normal individuals and non-traumatic chest pain patients (based on n=20 for each 
group from Chapter 4 research).  However it is important to note that this small set of 
plasma samples may not cover the entire range of hypoxanthine concentrations from a 
larger patient population, and further research work is necessary to optimize the 
hypoxanthine standard curve, as the goal of this chapter of research is the development of a 
rapid and simple method. 
Xanthine was found to be at a constant concentration (~6 µM) in both normal 
individuals and non-traumatic chest pain patient samples.  It is important to discuss why a 
standard curve of xanthine would not be used for this assay.  To prepare a standard curve 
of xanthine for computation of inosine and hypoxanthine concentrations would report 
erroneously low results, as xanthine only activates the XO enzyme once (xanthine to uric 
acid), whereas hypoxanthine activates the XO enzyme twice (hypoxanthine to xanthine to 
uric acid).  Since we are only interested in inosine and hypoxanthine concentrations for this 
research, and with xanthine levels constant, it was appropriate to prepare hypoxanthine 
standards (which incorporated total inosine to hypoxanthine conversion) for this research 
project. 
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Typical spreadsheets used for luminescence experiments on inosine, xanthine, and 
hypoxanthine evaluations include each reagent preparation, volume pipetted into the well, 
and target concentrations and are listed in Tables 11, 12, and 13, respectively.  Using the 
experimental spreadsheet for each component standard concentration range, plasma (20 µl) 
was pipetted into the microplate well with reagents (e.g. assay buffer, phosalin, PNP, 
uricase) either manually pipetted or injected using one direct injector; with the other direct 
injector used to inject the XO solution to start the reaction with pholasin and subsequent 
luminescence emission. 
5.2.5 Luminescence Computations 
All computations were performed using BMG Excel software (with built in 
macros) and data processing set points as defined by the method.  Figure 22 and 23 
represents a scan (plasma with 10 µM hypoxanthine) and the RLU tabulated results (e.g. 
BMG Excel Table 1, 2, and 3 in Figure 23) from raw data acquired over the analytical run 
and with data acquisition set at one data point per second.  The background (baseline) 
luminescence signal (labeled as Range 1 and presented in BMG Excel Table 1) can be 
caused by reagents (e.g. buffer, pholasin, PNP, plasma) and electronic noise and was 
calculated as the maximum RLU signal between scan times 100-118 seconds.  It would 
have been more appropriate to average the background RLU signal; however the BMG 
Excel software was written to have the same computation applied to both table ranges and 
does not currently allow the flexibility of independent computations on each individual 
table. 
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Table 11.  Typical spreadsheet used for inosine luminescence experiments. 
 
Final Inosine Conc. 
(200 ul well volume) Inosine Standard Inosine Pholasin 
Assay 
buffer PNP XO 
Total 
well 
volu
me 
[uM] (ul) WS [uM] (ul) (ul) (ul) (ul) (ul) 
0.0 0 0 50 70.0 40 40 200 
1.0 21.5 9.32 50 48.5 40 40 200 
2.5 53.6 9.32 50 16.4 40 40 200 
5.0 10.7 93.2 50 59.3 40 40 200 
10.0 21.5 93.2 50 48.5 40 40 200 
20.0 42.9 93.2 50 27.1 40 40 200 
30.0 64.4 93.2 50 5.6 40 40 200 
        
Example Plasma (ul)       
If plasma sample 1:10 dilution 20 0 50 50.0 40 40 200 
        
Notes:        
1.  Stock inosine [93.2 uM or 25 ug/ml] in DI.  Prepared by adding 25 mg in 1000 mL DI (or assay buffer). 
        
2.  Working stock (WS) WS-1 (9.32 uM) 100 ul stock inosine     
 (1:10 stock) 900 ul assay buffer     
        
3.  Final total inosine conc based on 200 ul well volume. 
        
4.  Pholasin conc [10 ug/ml]. 
Add 5 ml assay buffer to vial (50 ug pholasin from mollusca, Knight Scientific).   Store 
frozen. 
        
5.  XO conc [~676 mU XO / 
ml]. 
Pipet 40 ul stock (XO from bovine milk, Sigma) to 2 ml assay buffer.  Store 
refrigerated. 
        
6.  PNP conc [~701 mU PNP / 
ml]. 
Pipet 75 ul stock (PNP from human RBC, Sigma) to 2 ml assay buffer.  Store 
refrigerated. 
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Table 12.  Typical spreadsheet used for xanthine luminescence experiments. 
 
Final Xanthine Conc. 
(200 ul well volume) Xanthine 
Standard 
Xanthine Pholasin Assay buffer XO 
Total 
well 
volume 
[uM] (ul) WS [uM] (ul) (ul) (ul) (ul) 
0.0 0 0 50 110.0 40 200 
1.0 12.2 16.4 50 97.8 40 200 
2.5 30.5 16.4 50 79.5 40 200 
5.0 61.0 16.4 50 49.0 40 200 
10.0 12.2 164.4 50 97.8 40 200 
20.0 24.3 164.4 50 85.7 40 200 
30.0 36.5 164.4 50 73.5 40 200 
       
Example Plasma (ul)      
If plasma sample 1:10 dilution 20 0 50 90 40 200 
       
Notes:       
1.  Stock xanthine [164.4 uM or 25 ug/ml] in DI.  Prepared by adding 25 mg in 1000 mL DI (or assay buffer).  
       
2.  Working stock (WS) 
WS-1 (16.4 
uM) 100 ul stock xanthine    
 (1:10 stock) 900 ul assay buffer    
       
3.  Final xanthine conc based on 200 ul total well volume.     
       
4.  Pholasin conc [10 ug/ml]. 
Add 5 ml assay buffer to vial (50 ug pholasin from mollusca, Knight Scientific).   Store 
frozen. 
       
5.  XO conc [~676 mU XO / ml]. 
Pipet 40 ul stock (XO from bovine milk, Sigma) to 2 ml assay buffer. Store 
refrigerated. 
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Table 13.  Typical spreadsheet used for hypoxanthine luminescence experiments. 
 
Final Hypoxanthine 
Conc. 
(200 ul well volume) Hypoxanthine 
Standard 
Hypoxanthine Pholasin 
Assay 
buffer XO 
Total 
well 
volume 
[uM] (ul) WS [uM] (ul) (ul) (ul) (ul) 
0.0 0 0 50 110.0 40 200 
0.1 10.9 1.84 50 99.1 40 200 
0.2 21.8 1.84 50 88.2 40 200 
0.5 54.4 1.84 50 55.6 40 200 
1.0 10.9 18.37 50 99.1 40 200 
2.0 21.8 18.37 50 88.2 40 200 
5.0 5.4 183.7 50 104.6 40 200 
10.0 10.9 183.7 50 99.1 40 200 
       
Example Plasma (ul)      
If plasma sample 1:10 
dilution 20 0 50 90 40 200 
       
Notes:       
1.  Stock hypoxanthine [183.7 uM or 25 ug/ml] in DI.  Prepared by adding 25 mg in 1000 mL DI (or assay 
buffer).   
       
2.  Working stock (WS) WS-1 (18.37 uM) 100 ul stock hypoxanthine    
 (1:10 stock) 900 ul assay buffer    
       
 WS-2 (1.84 uM) 100 ul WS-1 hypoxanthine    
 (1:10 WS-1) 900 ul assay buffer    
       
3.  Final total hypoxanthine conc based on 200 ul well 
volume.      
       
4.  Pholasin conc [10 
ug/ml]. Add 5 ml assay buffer to vial (50 ug pholasin from mollusca, Knight Scientific).   Store frozen. 
       
5.  XO conc [~676 mU XO / 
ml]. Pipet 40 ul stock (XO from bovine milk, Sigma) to 2 ml assay buffer.  Store refrigerated. 
       
6.  Target range of nucleoside/purine assay (includes xanthine plus ino and hypo conversion to xanthine) is ~2 uM (normals) 
up to ~100 uM (ischemic). 
       
7.  Sensitivity and linearity of the nucleoside/purine assay (if 1:10 dilution of plasma) needs to be ~0.1 up to ~10 uM. 
 143
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22.  Typical BMG output luminescence scan for sample analysis of 10 µM 
hypoxanthine in plasma.  Range one (background RLU measurement between 100 and 120 
sec) and range two (peak height RLU measurement between 120 sec and 222 sec). 
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Figure 23.  BMG Excel computations, method and data processing set points, and file 
name are documented for GLP compliance.  Results are reported in excel cells based on 
microplate sample well location (96 well plates). 
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The peak luminescence signal from the generation of light from pholasin (labeled 
as Range 2 and presented in BMG Excel Table 2) and superoxide anion radicals was 
calculated as the maximum RLU peak height signal between scan times 119-222 seconds.  
BMG Excel Table 3 represents the net RLU and is calculated by subtracting the 
background signal (BMG Excel Table 1) from the peak luminescent signal (BMG Excel 
Table 2).  The use of the peak height response of the RLU was used for the computations 
on these plasma samples, as some patient plasma samples RLU responses were very slow 
to return to background (baseline) RLU levels.  The cause of the slow RLU signal return to 
baseline is unknown, but may be due to patient medications (e.g. vasodilators, salicylic 
acid) used for treatment of acute MI patients. 
As this luminescence method was set up for rapid screening purposes on potential 
non-traumatic chest pain patient samples from the ED, it was not developed to be a 
quantitative assay as was the validated HPLC-UV method (Chapter 4).  However, the 
luminescence method needed to be rapid (<10 min analysis), sensitive (use 20 ul plasma), 
specific (use of enzymes) and have high precision (repeatability) to be useful in the ED 
environment.  This luminescence method was developed to compare the RLU differences 
between healthy normal individual plasma samples (negative control) and samples from 
ED non-traumatic chest pain patients that may be experiencing acute cardiac ischemia. 
A comparison was made of the net RLU value between the non-traumatic chest 
pain patient and negative control sample, using a calculated 99% RLU reference cut-off 
value generated from healthy normal individuals, as the decision making RLU cut-off 
level.  Determining the 99% RLU cut-off value (which is beyond the scope of this 
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research) would best be determined using a large number of healthy normal individuals 
(e.g. >>100)) and calculated using the RLU mean value plus the 2.326 standard deviations 
(α=0.01, one tail, 99% confidence interval), and would be used to determine whether the 
patient has acute cardiac ischemia causing the reported chest pain. 
For example, if a non-traumatic chest pain patient net RLU was similar to a 
negative control sample net RLU, then the patient was most likely not having an acute 
cardiac ischemic event, but had some other type of medical condition (e.g. anxiety, 
heartburn) causing the reported chest pain.  However, if a patient’s net RLU was above the 
99% RLU reference cut-off value for healthy normal individuals, then the patient was 
probably experiencing an acute cardiac ischemic event, and would require immediate 
medical attention, as it may lead to acute MI and potential adverse outcome. 
5.3 Results and Discussion 
To setup the new luminometer equipment, a standardized plate mode luminescence 
test kit was bought (ABEL 61M Antioxidant Test Kit, Knight Scientific, Ltd) which 
evaluates antioxidant capability using xanthine/xanthine oxidase and pholasin.  This test 
kit was used to qualify the new luminometer equipment using a standardized plate mode 
(glow technique).  However, method modifications were necessary as the plate mode 
analysis run time was approximately 30 min and had low sensitivity (Figure 24) as it is 
developed primarily for antioxidant and glow kinetic type studies, which would be 
insufficient for our research objective of a rapid and sensitive assay. 
Adjustments were made to the level of XO used for analysis to increase the 
reaction rate (flash mode) and the incubation time of PNP enzyme for plasma inosine 
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Figure 24.  Chart of relative light units (RLU) versus time (sec) for 30 µM xanthine/XO 
plate mode kinetics.  The profile demonstrates successful new equipment setup and 
operation using a commercial test kit for antioxidant evaluation (ABEL 61-M, Knight 
Scientific).  Two individual samples overlay with analysis time ~30 min. 
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conversion to hypoxanthine.  The starting level of XO enzyme level for the plate mode was 
approximately 10.25 mU/ml after reconstitution with assay buffer.  With adjustment of XO 
to increase the concentration, the final working concentration was approximately 676 
mU/ml.  This resulted in an analysis time reduction from approximately 30 min to 5 min 
(Figure 25).  Since the commercial kit from Knight Scientific (plate mode) was set up for 
xanthine/xanthine oxidase analysis and studies on material antioxidant capabilities, it was 
necessary to increase the XO level to additionally incorporate plasma hypoxanthine levels, 
but more importantly to reduce the time of analysis to under 10 min (i.e. switch from glow 
mode to flash mode kinetics). 
A standard curve of hypoxanthine was evaluated at concentrations from 2.3 to 30.3 
µM and demonstrated sufficient linearity (normal linear regression) with correlation 
coefficient >0.9990 (n=2).  The incubation time of purine nucleoside phosphorylase was 
evaluated at 60 and 120 second equilibration times using 10 μM inosine as the substrate 
with the monitoring of hypoxanthine level (Figure 26).  Therefore, the PNP incubation 
time should remain set at 120 sec to allow for complete inosine to hypoxanthine 
conversion, with subsequent XO injection to start the luminescence reaction.  For future 
work, one possible way to reduce the overall analysis time would be to add the PNP 
enzyme to the sample collection tube (e.g. BD vacuutainer), with inosine conversion then 
occurring during the whole blood to plasma centrifugation step.  If this centrifugation 
technique utilizing PNP in the vacuutainer results in complete inosine to hypoxanthine 
conversion, it would eliminate the need for the 120 sec PNP incubation time; and reduce 
 149
 
 
 
Figure 25. Chart demonstrating a significantly reduced analysis time by utilizing increased 
amounts of XO (from ~10.3 mU/ml to ~676 mU/ml) and continuous microplate mixing.  
Analysis time ~3.7 min. 
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Figure 26. Charts depicting inosine and PNP incubation time and conversion study.  
Evaluation of 60 and 120 sec PNP incubation times, with 120 sec demonstrating the 
complete conversion of inosine to hypoxanthine.  The 10 µM inosine with PNP conversion 
RLU responses (n=2) overlays completely against the 10 µM hypoxanthine standard. 
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the analysis time to only 30 seconds (assumes injection of XO at 0.1 sec and measurement 
of peak height RLU response). 
A study of the effect of plasma uric acid on luminescence response was performed.  
Since uric acid is found in plasma at relatively higher concentrations (normal range ~350-
475 µM) and is a known antioxidant, it was important to evaluate its potential effect on the 
luminescence signal.  As seen in Figure 27, the uric acid’s antioxidant affects decreases the 
luminescence signal (~50% quenching).  To address the uric acid, an experiment was 
performed using strong anion exchange (SAX) resin to remove organic anions from the 
plasma matrix.  Also seen in Figure 27 is a 1:100 dilution of plasma and subsequent use of 
the SAX pipet tip (Varian, Inc, CA, USA); both demonstrated that removal of potential 
interfering organic acids (e.g. urate at pH 7.4) resulted with an increase in luminescence 
response and sensitivity.  Since the blank plasma used had approximately 500 nM 
hypoxanthine, the 1:100 dilution using deionized water and subsequent use of SAX sorbent 
makes detection levels of hypoxanthine at the pM levels attainable. 
A second approach to eliminate the uric acid was to utilize uricase (~1.1 U/ml from 
Arthrobacter globiformis bacteria, Sigma, USA) during the PNP incubation time in an 
attempt to eliminate the endogenous uric acid.  As seen in Figure 28, it appears that the XO 
enzyme is deactivated (product inhibition) by the presence of large amounts of by-product 
hydrogen peroxide that is generated by uricase activity.  As one by-product of XO activity 
is the production of hydrogen peroxide, this finding was not completely surprising due to 
the effects of product inhibition on XO enzyme turnover.  One possible solution to 
eliminate the generated hydrogen peroxide is to use horseradish peroxidase, which 
 152
10 uM Hypo with UA in Assay Buffer
0
200,000
400,000
600,000
800,000
1,000,000
0 50 100 150 200
Time (sec)
RL
U
74.4 uM UA (gout)
37.2 uM UA (normals)
10 uM Hypo
 
ProMedDX 11136468 Plasma (Heparin)
Normals (no dilution vs 1:100 vs 1:100 with SAX)
0
2000
4000
6000
8000
10000
12000
0 50 100 150 200
Time (sec)
R
LU
Promed Blk
11136468
1:100 dil
1:100 dil and SAX
 
Figure 27. Charts demonstrating effects of uric acid (human physiological levels) on 
pholasin luminescence signal.  High levels of uric acid (in buffer) can quench the 
luminescence by more than 50%.  Treatment of plasma (1:100 dilution) and use of strong 
anion exchange (SAX) can reduce antioxidant effect on the luminescence signal and 
increase method sensitivity. 
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Figure 28. Chart demonstrating the effect of uricase on basal uric acid levels (normal 
healthy individual) and with fortification of 10 µM hypoxanthine.  The generation of 
hydrogen peroxide (by-product) from uricase enzymatic conversion of uric acid to 
allantoin caused XO inactivity (potentially from hydrogen peroxide product inhibition on 
XO effect). 
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catalyzes hydrogen peroxide to products water and oxygen, but this additional enzyme 
would only add to the complexity and cost of the analysis and therefore not evaluated. 
However, the use of the both uricase and SAX pipet tip technology to eliminate 
organic acids (e.g. uric acid) was probably not necessary to use, as differences in 
luminescence response between the healthy normal individuals and confirmed acute MI 
patients (elevated cTnT levels) was significant (t-test, α=0.05, p<0.01), when using the 
99% percentile (α=0.01, one tail, 2.326 standard deviations for n=6) as the calculated 
biomarker cut-off reference value for acute cardiac ischemia (Figure 29).  Even though this 
research utilized a small sample set for evaluation (n=6 for each group), the 99% cut-off 
for healthy normal individuals was 5,946 RLU, with all six cTnT patients clearly above 
this calculated decision point cut-off RLU level.  The luminescence method was optimized 
for rapid evaluation of hypoxanthine in plasma to potentially be used in an ED clinical type 
environment.  For this research study, method parameters such as calibration, repeatability 
and limit of detection were evaluated using hypoxanthine standards. 
The method demonstrated linearity from 2.3-30.3 µM hypoxanthine in assay buffer 
(R=0.9990, n=2) (Figure 30).  This range covered the low and midpoint total hypoxanthine 
concentrations of samples from HPLC analysis of healthy individuals and non-traumatic 
chest pain patients (Figure 16), and focused on the potential biomarker cut-off 
concentration for this small group of samples (n=20).  Repeatability (n=3) was evaluated 
by fortification of plasma at basal (~0.5 µM) and 1.5 µM hypoxanthine concentrations 
(final well levels) and demonstrated by consistent RLU overlays (Figure 31). 
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Figure 29.  Charts demonstrating healthy normal individuals and patients with confirmed 
acute MI (hospital documented elevated levels of cTnT).  All cTnT patient samples RLU 
response were clearly above the calculated 99% cut-off reference value (5,944 RLU) for 
healthy normal individuals (n=6 for each group).  HPLC values for total hypoxanthine 
(from Chapter 4) and cTnT values (from ProMedDx) are listed in the legend. 
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Figure 30.  Hypoxanthine standard curve in assay buffer ranging from 2.3 to 30.3 µM 
demonstrating sufficient linearity and back-calculated hypoxanthine concentrations. 
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Figure 31.  Charts demonstrating repeatability of the luminescence assay.  Healthy normal 
individual (basal level, ~0.5 µM hypoxanthine) and fortified sample (1.5 µM 
hypoxanthine) assayed three consecutive times.  Overlay of profiles demonstrate plasma 
sample repeatability. 
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5.4 Conclusion 
 A rapid luminescence method was developed for the detection of inosine and 
hypoxanthine in human plasma.  Using only 20 ul of plasma (heparin) and instrument 
direct injectors, the method allowed for the rapid (<5 min) detection of total hypoxanthine 
(as inosine is converted to hypoxanthine using enzyme PNP) concentrations, which may 
potentially be used as a biomarker of acute cardiac ischemia.  The use of a hypothetical 
cut-off level (e.g. 99% confidence) relative luminescence unit (RLU) for decision making 
(i.e. positive level, negative level) may be the most effective use of this rapid screening 
assay.  The method was utilized for evaluation of plasma samples from healthy individuals 
and cardiac patients with confirmed acute myocardial infarction (hospital documented 
elevated plasma cTnT levels), and demonstrated the potential of this rapid assay to be used 
as a diagnostic tool, for use by emergency department services personnel on non-traumatic 
chest pain patients suspected of undergoing acute cardiac ischemia. 
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CHAPTER 6. Summary Research Conclusions and Potential Limitations 
 
 
 
 
With cardiovascular disease (e.g. acute myocardial infarction (MI)) being one of 
the leading causes of mortality in the world, a rapid patient assessment, diagnosis and 
treatment is important to improving patient outcomes.  This research investigation focused 
on the use of endogenous plasma levels of inosine (hypoxanthine precursor) and 
hypoxanthine, as a potential diagnostic tool for use in the evaluation of emergency 
department non-traumatic chest pain patients.  The research was divided into three phases 
with highlighted research goals as follows:  Phase I. Animal (mouse) experiments to 
identify potential biomarker(s) and demonstrate biomarker proof-of-concept and disease 
condition (acute cardiac ischemia); Phase II. Evaluation of healthy normal individuals and 
ED non-traumatic chest pain patients plasma samples for the identified biomarker(s) from 
Phase I studies; Phase III. Development of a sensitive and rapid clinical assay (<10 min 
analysis goal) for detection of inosine and hypoxanthine in human plasma. 
Phase I research utilized the ICR mouse model for all experiments.  Briefly, the 
mice were anaesthetized; hearts removed and isolated onto a Langendorff apparatus, with 
Krebs buffer solution providing physiological nutrients.  For ischemic conditions, the 
isolated heart experiments consisted of 30 min stabilization, 20 min zero-flow global 
ischemia, followed by 30 min of Krebs buffer reperfusion.  Time-matched studies were 
carried out for control (non-ischemic) and test (ischemic) experimental groups.  Upon heart 
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reperfusion, approximately 1.5 ml samples of the Krebs buffered perfusate from isolated 
mouse hearts were collected at time-points (0, 1, 3, 5, 10 and 20 min) and stored frozen (-
20°C) until analysis.  An HPLC-UV method was developed and validated for sample 
analysis with LC-MS used for biomarker identification.  Results from this phase of 
research demonstrated the significant increase in levels of inosine (t-test, p<0.05) and 
elevated levels of hypoxanthine from isolated mouse hearts undergoing 20 min acute 
global ischemia relative to the non-ischemia control group. 
An evaluation of the effects of salicylic acid (SA) in Krebs buffer solution was 
made, as aspirin (ASA, salicylic acid precursor) is used as part of the initial treatment for 
patients suspected of undergoing acute MI, to reduce platelet formation at the site of the 
thrombus (clot).  Results of mouse hearts undergoing 20 min acute global ischemia and 
exposure to 0.1 and 1.0 mM SA concentrations both demonstrated a potentiation of 
effluxed inosine from the affected heart tissue.  As any further work using SA was beyond 
the scope of this research project, however it is strongly recommended that additional 
research using animal models are performed on the apparent adverse effects of ASA and 
SA on ATP catabolism under conditions of acute cardiac ischemia.  Knowing how 
widespread ASA is used for other medical treatments (e.g. analgesia, rheumatoid arthritis) 
and the possibility of those patients one day experiencing an acute cardiac ischemic event, 
supports the recommendation of further research on aspirin and its metabolite, salicylic 
acid on ATP catabolism. 
Phase II research evaluated plasma samples representing healthy normal 
individuals and local hospital emergency department non-traumatic chest pain patients.  
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Samples were evaluated using a modified and validated HPLC-UV method from Phase I 
studies.  An evaluation of sample collection (matched subject sets of plasma (heparin) and 
serum separator tube (SST) samples) was performed to determine if inosine and 
hypoxanthine component differences exist between these two frequently used blood 
collection techniques.  Results of this phase of research demonstrated elevated amounts of 
hypoxanthine concentrations (~19% positive bias) from blood samples collected using SST 
tubes, relative to the collection of plasma (heparin).  The use of the anticoagulant heparin 
for obtaining blood samples for these test procedures is recommended; as it eliminates the 
potential positive bias in hypoxanthine concentrations, and it ultimately saves time (SST 
requires a recommended clotting time of 30 min prior to the centrifugation step).  
Significant differences (t-test, p<0.05) were found for plasma concentrations of inosine and 
hypoxanthine detected from emergency department patients presenting with non-traumatic 
chest pain relative to healthy normal individuals. 
Phase III research focused on the initial development of a rapid (<10 min analysis 
goal) luminescence assay for plasma inosine and hypoxanthine, to potentially be used in 
hospital clinical laboratory or point-of-care environments.  Briefly, the assay utilized 20 ul 
plasma with enzymes purine nucleoside phosphorylase (PNP) used for conversion of 
plasma inosine to hypoxanthine, and xanthine oxidase (XO) used for conversion of 
hypoxanthine to xanthine, and xanthine to uric acid.  One metabolic by-product of the XO 
enzymatic conversion is the generation of highly reactive superoxide anion radicals, which 
can react with pholasin® (a photoprotein) to generate blue-green light measurable using a 
luminometer. 
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The luminescence assay was utilized for rapid detection of plasma concentrations 
of inosine and hypoxanthine obtained from healthy normal individuals and hospital acute 
MI patients (hospital documented elevated cTnT plasma levels).  Using a calculated 99th 
RLU (relative luminescence unit) percentile reference cut-off level from the healthy 
normal individuals (n=6), all six acute MI patients with elevated levels of cTnT had 
hypoxanthine levels above the 99th RLU percentile cut-off level.  These results, although 
having limited data (n=6 for each group), demonstrate the potential utility of using total 
hypoxanthine (inosine plus hypoxanthine levels) as a biomarker of cardiac ischemic 
conditions and the luminescence method as a rapid, simple and sensitive measurement 
technique. 
 For evaluation of human plasma samples, the use of the HPLC-UV or microplate 
luminometer both demonstrated the necessary sensitivity and specificity for determination 
of inosine and hypoxanthine components in human plasma.  However, each technique 
offered certain specific advantages on its particular use.  The HPLC-UV technique offers 
complete separation and quantification of each component of interest without interferences 
from endogenous uric acid, but the analytical run time of approximately 20 min may be too 
long, if used in a hospital emergency department environment.  The luminometer 
technique offered a rapid analysis (<5 min), which is ideal for the emergency department 
environment, but it does not individually measure inosine and hypoxanthine components, 
and may have potential interferences (e.g. high plasma uric acids in gout patients or 
individuals which may take antioxidant type GNC supplements such as ascorbic acid or 
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polyphenols) that quench the luminescence emission from pholasin (i.e. signal suppression 
with potential false negative results). 
 Since biomarker sensitivity and specificity are important parameters to evaluate, it 
is important to briefly discuss them relative to this research project’s results.  Total 
hypoxanthine (inosine and hypoxanthine combined) is found endogenously in the body 
from normal purine metabolism, thus making the specificity of using total hypoxanthine as 
a biomarker of acute cardiac ischemia low, as it is not totally specific to heart tissue (as are 
the cardiac troponins).  However, under patient conditions of acute cardiac ischemia, the 
increase in ATP catabolic by-products found in the bloodstream can certainly be attributed 
to the heart cell mitochondria’s inability to produce sufficient amounts of ATP; thus 
ultimately resulting in the efflux of ATP catabolic by-products inosine and hypoxanthine 
out of the heart tissue and into the bloodstream.  This higher concentration level of total 
hypoxanthine (inosine and hypoxanthine) and the ED patient’s chief complaint of non-
traumatic chest pain; potentially indicates an acute cardiac ischemic condition and warrants 
immediate medical treatment.  It should be mentioned that total hypoxanthine plasma 
levels may also be significantly elevated from other potential ischemic conditions (e.g. 
ischemic stroke, angina). 
For biomarker sensitivity, luminescence technology is one of the most sensitive 
analytical techniques currently available, and the results from Phase III demonstrated 
sufficient sensitivity for total hypoxanthine in normal healthy individuals and cTnT 
patients, even without plasma sample treatment (no extractions or preparation steps were 
necessary).  The recently FDA cleared IMA test for cardiac ischemia has the same 
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biomarker properties (low specificity, high sensitivity), and was approved to be used in 
conjunction with other test (ECG and cardiac troponin) to improve patient diagnostic 
accuracy.  Our proposed candidate biomarker may follow the same path as the FDA 
cleared IMA biomarker; however it should be emphasized that one major difference 
between these two biomarkers is the albumin that is modified from the ischemic heart 
tissue is found in the bloodstream, and not effluxed from the cardiac tissue itself (thus the 
low specificity).  From the findings of this research, the total hypoxanthine levels that are 
found elevated from acute cardiac ischemic conditions would be effluxed from the affected 
heart issue into the bloodstream, thus potentially making hypoxanthine a more specific 
biomarker than IMA for acute cardiac ischemia. 
 Some other potential sources of error in test results are shown in Table 14.  
Individuals born with enzyme deficiencies (e.g. adenosine deaminase (ADA), purine 
nucleoside phosphorylase) may cause erroneous results (e.g. false negative and false 
positive results), however these individuals should also have immunological problems 
which are associated with these enzyme deficiencies, and therefore communicated to 
emergency department personnel as part of obtaining the patient medical history. 
Kidney disease and kidney failure are two medical conditions which may lead to 
potential errors in inosine and hypoxanthine test results.  As elimination of most 
substances from the blood stream is severely compromised in these patient populations, 
even small polar components such as inosine and hypoxanthine may be retained in the 
blood stream, leading to elevated blood concentrations and potential false positive results.  
Kidney disease typically requires chronic treatments (e.g. medication) and individuals 
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Table 14.  Listing of enzyme deficiencies, food sources and medical conditions which 
many contribute to errors in interpreting test results. 
Potential Errors in Results 
• ADA Deficiency - ↑ Adeno, ↓ Ino and ↓ Hypo 
(causes immune problems) – potential false negative 
 
• PNP Deficiency - ↑ Ino, ↓ Hypo (causes immune problems) – 
potential false positive 
 
• XO Deficiency - ↑ Xan, slight ↑  Hypo (may cause kidney problems) 
 
• Kidney failure or disease 
 
• Food sources containing purines – organ meats, mushrooms, 
spinach, yeast, peas, beer 
 
• Inosine – GNC (enhance athletic performance) 
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having this disease are typically aware of their medical condition.  However, kidney failure 
may occur acutely from a traumatic event (e.g. acute kidney failure resulting from a ladder 
fall), with the individual unaware of an acute kidney failure condition that can rapidly lead 
to a significant buildup of waste products in their blood stream (thus leading to potential 
erroneous test results).  Individuals with XO deficiency or taking allopurinol (medication 
commonly used for gout treatment), should have elevated levels of xanthine in the blood 
potentially causing false positive results.  Other sources of exogenous purines that may 
cause potential errors in test results; would be from a high consumption of purine 
containing food sources (e.g. organ meats, spinach, and beer) and the use of GNC 
supplements (e.g. inosine advertised to enhance athletic performance). 
 In conclusion, it has been demonstrated using our animal model that inosine, a 
potential biomarker of acute cardiac ischemia, was significantly effluxed from isolated 
mouse hearts undergoing 20 min acute global ischemia (Phase I results).  The significant 
levels of effluxed inosine may best be explained by the acute cardiac ischemic event, 
which causes ATP by-product catabolism and the formation and efflux of inosine by the 
affected cardiac tissue (proof-of-biology).  Subsequent work (Phase II), using human 
plasma samples obtained from hospital emergency department patients with non-traumatic 
chest pain, indicated elevated levels of inosine and significant levels of hypoxanthine 
(inosine metabolism occurs immediately in red blood cells), thus supporting the results 
from Phase I studies. 
In Phase III and finishing the research project objectives, the development of a 
potential clinical assay was achieved to rapidly measure inosine and hypoxanthine levels 
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using only 20 µl of human plasma, in less than 5 minutes.  As there are more than 10 
medical conditions that may cause non-traumatic chest pain (e.g. angina, anxiety, 
heartburn, acid reflux, etc.), it would benefit emergency medical service providers to have 
additional biomarker(s) of acute cardiac ischemia and a rapid clinical diagnostic assay to 
assist in patient diagnosis to either rule-in (RIMI) or rule-out (ROMI) acute MI.  The 
results of this work may one day help to answer the medical communities request for 
additional biomarker(s) of acute cardiac ischemia, and ultimately lead to prompter 
treatment for the millions of non-traumatic chest pain patients that visit hospital emergency 
departments every year. 
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Poster presented at Pittcon 2006 Analytical Exposition (Orlando, Florida, March 2006). 
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Farthing IRB #4336 Research Synopsis 
I. Title:  Evaluation of Potential Biomarker(s) in Human Plasma for Initial Cardiac 
Ischemia 
II. Investigators:  Dr. Domenic Sica M.D., Don Farthing (Graduate Student) 
III. Hypothesis:  Our hypothesis is that endogenous inosine (purine) may be present in 
human plasma from the catabolism of ATP in ischemic heart tissue.  Therefore, inosine 
may be a potential biomarker of initial human cardiac ischemia prior to heart tissue 
necrosis (protein biomarkers released). 
IV.     Specific Aims:  Our specific aim of this research is to determine if inosine is present 
in plasma samples from patients that were admitted for treatment of myocardial infarction 
(MI).  If inosine is present in patients diagnosed and treated for MI (test) and is not present 
in plasma samples from patients without MI (control), we will pursue developing a 
possible point-of-care technique to determine inosine levels in plasma. 
V.     Background and Significance:  Each year in the US, approximately 7-8 million 
patients arrive with non-traumatic chest pain to hospital emergency rooms.  Medical 
personnel are challenged to properly diagnose and treat these patients.  It is estimated that 
approximately 2-5% of these patients are experiencing myocardial infarction, but due to 
misdiagnosis, they are incorrectly discharged leading to medical malpractice.  Thus, 
emergency medical services to patients would benefit by having a biomarker to help 
differentiate initial cardiac ischemic conditions from other noncardiac illnesses, which also 
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may cause chest pain (e.g. GERD, heartburn, asthma, gallstones, pneumonia, and 
pancreatitis). 
VI.      Preliminary Progress/Data Report:  Initial animal experiments were performed 
during 2003-2004 at VCU (Dr. Lei Xi, IACUC #0405-2957, Dept. of Internal Medicine, 
Div. of Cardiology) using the ICR outbred mouse strain.  The mice were anaesthetised, 
hearts surgically removed and isolated for experiments using a Langendorff system.  The 
hearts were perfused using Krebs buffered solution at pH 7.4 and contained 
95%O2:5%CO2.  Global cardiac ischemia was initiated by adjusting the Krebs solution to a 
zero flow rate for 20 min.  Upon heart reperfusion with 95%O2:5%CO2, samples of Krebs 
solution eluant from the heart were collected at predetermined times and frozen prior to 
HPLC analysis.  For HPLC analysis, 100 µL of the collected sample was injected neat, 
using chromatography conditions consisting of a C18 reversed phase column, gradient 
mobile phase and diode array detection. 
VII.   Preliminary animal test results from above initial research indicated that inosine 
may be a potential biomarker indicative of initial mouse cardiac ischemia.  Inosine and 
xanthine-like products (e.g. hypoxanthine, xanthine and uric acid) were found at higher 
levels in mice subjected to global cardiac ischemia versus non-ischemic conditions.  These 
results can be explained by ischemic myocytes undergoing nucleotide purine catabolism in 
the absence of oxygen, which activates normally dormant cellular enzymes and generates 
degradative products (e.g. adenosine, inosine, hypoxanthine and xanthine) from the 
breakdown of ATP. 
 203
VIII. Research Method & Design:  As part of my Ph.D. thesis (D. Farthing, MCV 
graduate student, Dept. of Pharmaceutics), I am requesting IRB approval to obtain existing 
plasma samples from cardiovascular (ischemic) diseased patients that have received 
treatment from VCU Medical Center Hospitals.  These patients were diagnosed with 
myocardial infarction and subsequently treated at VCU Medical Center Hospitals.  All 
plasma samples (25 from non-ischemic patients (controls) and 25 from ischemic patients 
(tests)) will be obtained from patients previously admitted for medical treatment.  The 
plasma samples (frozen and obtained from the Dept. of Clinical Chemistry) will be 
stripped of any patient information on the sample tubes for compliance with current patient 
privacy laws (HIPPA).  The samples will be coded as control or test samples (e.g. 
numbered 1-25) by Dept. of Clinical Chemistry personnel who have been trained on 
HIPPA regulations.  Human plasma samples obtained will be extracted and evaluated for 
inosine levels using a developed HPLC method at an MCV laboratory (Dr. Domenic Sica, 
Dept. of Internal Medicine, Division of Clinical Pharmacology).  The results and 
interpretation of these experiments will likely be submitted for publication in a scientific 
journal (e.g. Clinical Chemistry) and used as part of D. Farthing’s Ph.D. thesis.  I am 
requesting an expedited review from Federal Regulations for the Protection of Human 
Subjects (45 CFR 46) based on the following reason.  All plasma samples obtained will be 
existing samples that were initially used for patient diagnostic information. 
IX. Statistical Analysis:  Statistical analysis is not applicable as inosine from the pateint’s 
ischemic cardiac tissue will either be present or not present in the plasma samples.  The 
reason for this all or nothing expectation is that the biological half-life of inosine has been 
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published to be approximately one minute in humans so it may be completely metabolised 
and not detected.  However, if detected, it may indicate that inosine is a potential 
biomarker of initial human cardiac ischemia prior to heart tissue necrosis. 
X.      Data and Safety Monitoring:  Not applicable 
XI.      Human Subjects Instructions:  Not applicable 
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APPENDIX D 
 
Additional plasma purchased from ProMedDx and evaluated using HPLC. 
     Ino Hypo      
Sample 
Type Matrix 
ProMedDx 
# Gender Age [µM] [µM] Comments        
Ctrl-1 
Plasma (Li 
Heparin) 10372009 M 51 <0.9 <1.8 Normals (PromedDx)    
Ctrl-1 Serum (no gel)    <0.9 <1.8 "     
Ctrl-2 
Plasma (Li 
Heparin) 10372011 M 50 <0.9 1.5 "     
Ctrl-2 Serum (no gel)    <0.9 1.3 "     
Ctrl-3 
Plasma (Li 
Heparin) 10372018 M 20 <0.9 2.2 "     
Ctrl-3 Serum (no gel)    <0.9 2.1 "     
Ctrl-4 
Plasma (Li 
Heparin) 10372020 M 34 <0.9 1.9 "     
Ctrl-4 Serum (no gel)    <0.9 1.9 "     
Ctrl-5 
Plasma (Li 
Heparin) 10372026 M 49 <0.9 1.5 "     
Ctrl-5 Serum (no gel)    <0.9 2.0 "     
Ctrl-6 
Plasma (Li 
Heparin) 10372027 M 18 <0.9 3.4 "     
Ctrl-6 Serum (no gel)    <0.9 4.6 "     
Ctrl-7 
Plasma (Li 
Heparin) 10372028 M 38 <0.9 1.3 "     
Ctrl-7 Serum (no gel)    <0.9 1.3 "     
Ctrl-8 
Plasma (Li 
Heparin) 10372030 M 38 <0.9 <1.8 "     
Ctrl-8 Serum (no gel)    <0.9 <1.8 "     
Ctrl-9 
Plasma (Li 
Heparin) 10372032 M 43 <0.9 1.5 "     
Ctrl-9 Serum (no gel)    <0.9 1.5 "     
Ctrl-10 
Plasma (Li 
Heparin) 10372035 M 38 <0.9 <1.8 "     
Ctrl-10 Serum (no gel)       <0.9 <1.8 "        
HT-1 
Plasma (Li 
Heparin) 10417810 F 25 <0.9 2.2 Hypertension (PromedDx)    
HT-1 Serum SST    0.7 7.8 Patients BP 210/105, Hct   
HT-2 
Plasma (Li 
Heparin) 10417811 M 44 <0.9 2.9 "     
HT-2 Serum SST    0.8 25.8 " BP 150/104, Glipizide   
HT-3 
Plasma (Li 
Heparin) 10417814 F 30 <0.9 2.0 "     
HT-3 Serum SST    3.6 12.5 " BP 180/98, Tenormin   
HT-4 
Plasma (Li 
Heparin) 10425962 F 43 <0.9 7.3 "     
HT-4 Serum SST    <0.9 25.8 " BP 150/110, Tenormin   
HT-5 
Plasma (Li 
Heparin) 10425963 F 37 <0.9 1.1 "     
HT-5 Serum SST    <0.9 3.8 " BP 160/102, Tenormin   
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HT-6 
Plasma (Li 
Heparin) 10425964 F 52 <0.9 2.5 "     
HT-6 Serum SST    <0.9 11.4 " BP 165/103, Hct   
HT-7 
Plasma (Li 
Heparin) 10425965 F 39 <0.9 5.9 "     
HT-7 Serum SST    <0.9 30.0 " BP 175/82, Hct   
HT-8 
Plasma (Li 
Heparin) 10425966 M 29 <0.9 1.3 "     
HT-8 Serum SST    0.7 12.8 " BP 160/89, Lotensin   
HT-9 
Plasma (Li 
Heparin) 10425968 F 45 <0.9 1.4 "     
HT-9 Serum SST    3.6 14.9 " BP 148/98, Hct   
HT-10 
Plasma (Li 
Heparin) 10425971 F 25 <0.9 0.8 "     
HT-10 Serum SST       2.4 13.7 " BP 140/98, Hct and Lisinopril  
cTnI-1 
Plasma (Li 
Heparin) 11075181 F 86 3.6 21.7 MI Patients (PromedDx)    
cTnI-1 Serum SST    0.9 9.1 " cTnI 0.4 ug/L   
cTnI-2 
Plasma (Li 
Heparin) 11075182 M 86 5.3 3.3 "     
cTnI-2 Serum SST    4.4 6.3 " 0.5    
cTnI-3 
Plasma (Li 
Heparin) 11075183 F 71 <0.9 7.2 "     
cTnI-3 Serum SST    <0.9 7.2 " 0.8    
cTnI-4 
Plasma (Li 
Heparin) 11075186 F 74 <0.9 6.2 "     
cTnI-4 Serum SST    <0.9 7.4 " 0.4    
cTnI-5 
Plasma (Li 
Heparin) 11075187 F 90 1.0 7.3 "     
cTnI-5 Serum SST    0.8 13.7 " 0.6    
cTnI-6 
Plasma (Li 
Heparin) 11075189 F 59 <0.9 9.7 "     
cTnI-6 Serum SST    2.0 9.2 " 0.5    
cTnI-7 
Plasma (Li 
Heparin) 11075193 F 54 <0.9 4.6 "     
cTnI-7 Serum SST    1.2 19.8 " 0.9    
cTnI-8 
Plasma (Li 
Heparin) 11107700 F 49 <0.9 33.6 "     
cTnI-8 Serum SST    <0.9 10.9 " 0.6    
cTnI-9 
Plasma (Li 
Heparin) 11109491 M 90 <0.9 12.7 "     
cTnI-9 Serum SST    <0.9 4.1 " 31.9    
cTnI-10 
Plasma (Li 
Heparin) 11109492 F 54 <0.9 31.2 "     
cTnI-10 Serum SST    <0.9 14.3 " 1.1    
            
Notes:            
1. ProMedDX (Norton, MA), a FDA registered biorepository with all samples acquired following IRB approval.    
2. Ino= Inosine, Hypo= hypoxanthine, HT = hypertension, cTnI = cardiac tropoinin I.     
3. Plasma and serum samples evaluated on same analytical run using calibration curve (DI standards) and controls (plasma).   
4. HT and cTnI samples from same hospital, using SST tubes (gel) and following package insert (clotting and spin time, centrifugal force 
etc). (per PromedDx). 
5. Controls from normal donor collection center using red top serum tubes (no gel) per PromedDx.     
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hiring, performance appraisals, disciplinary action, training, capital and expense budget, job 
and work orders.  Technical audit team member for PM flavor suppliers. 
 
Job Title: Sr. Analyst, Quality Assurance, 1990-1995 
Location: Flavor Center, Philip Morris U.S.A., Richmond, VA 23261 
Duties: Evaluate, modify, and implement analytical procedures.  Troubleshoot and maintain 
GC, HPLC, and GC/MS equipment.  Responsible for export regulatory program.  Train 
employees on analytical procedures. 
 
Job Title: Research Bioanalytical Chemist (Consultant), 1988-2007 (part-time) 
Location: Dept. of Internal Medicine, Division of Nephrology, Section of Clinical 
Pharmacology and Hypertension, MCV, Richmond, VA 23298 
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Duties: Method development, validation, and analysis of drugs in biological matrices.  
Maintenance and troubleshooting of GC and HPLC equipment.  Prepare manuscripts for 
publication in scientific journals. 
 
Job Title: Supervisor, Quality Assurance, 1988-1990 
Location: Flavor Center, Philip Morris U.S.A., Richmond, VA 23261 
Duties: Supervise flavor manufacturing QA lab.  HPLC, GC, physical testing and sensory 
evaluations on raw materials and blended flavors.  Quality control and data evaluation.  Write 
internal procedures for quality assurance manuals. 
 
Job Title: Analytical Chemist, 1987-1988 
Location: Consolidated Labs, State of Virginia, Richmond, VA 23298 
Duties: HPLC, GC, AA, and DCP analysis on samples from industrial hygienist.  Implement 
and/or modify analytical OSHA methods.  Train analytical technicians on procedures and 
data calculations.  Wrote basic programs for quality control used for instrumental results. 
 
Job Title: Lab Specialist, 1984-1987 
Location: Department of Pharmaceutics, MCV, Richmond, VA 23298 
Duties: Develop analytical methods for evaluating drugs in biological fluids using HPLC and 
GC. Computer evaluation of analytical data.  Instrument maintenance and troubleshooting.  
Training analytical technicians and graduate students on analytical procedures. 
 
Technical Publications and Posters 
1. Farthing D., Sica D., Gehr T., Larus T., Farthing C., Karnes H.T.  Rapid luminescence 
method for determination of inosine and hypoxanthine in human plasma.  Poster Pittcon 
(New Orleans La, March 2008). 
2. Farthing C., Farthing D., Brophy D., Larus T., Maynor L., Fakhry I. and Gehr T. W.B..  
HPLC determination of cefepime and cefazolin in human plasma and dialysate.  
Manuscript accepted by Chromatographia (Dec 2007). 
3. Maynor L.M., Carl D.E., Matzke G.R., Gehr T. W.B., Farthing C., Farthing D., Brophy 
D.F..  An in vivo-In vitro study of cefepime and cefazolin clearance during high flux 
hemodialysis.  Manuscript submitted to Pharmacotherapy (Sept 2007). 
4. Farthing D., Gehr L., Karnes H.T., Sica D., Gehr T., Larus T., Farthing C. and Xi L.  
Dose-dependent effects of salicylic acid on post-ischemic ventricular function and purine 
efflux in isolated mouse hearts.  Biomarkers (2007) 12(6):623:634. 
5. Farthing D., Sica D., Gehr T., Wilson B., Fakhry I., Larus T., Farthing C. and Karnes H.T.  
A simple and sensitive HPLC method for determination of inosine and hypoxanthine in 
human plasma from healthy volunteers and patients presenting with chest pain and 
potential acute cardiac ischemia. (J of Chrom B (2007) 854:158-164. 
6. Farthing D., Sica D., Gehr L., Larus T. Karnes H.T., and Xi L.  Effect of salicylic acid on 
ischemia-reperfusion injury in isolated mouse hearts.  Poster Pittcon (Orlando Fl, March 
2006). 
 209
7. Farthing D., Xi L., Gehr L., Sica D., Larus T., and Karnes H.T.  HPLC determination 
of a potential biomarker of initial cardiac ischemia using isolated mouse hearts.  Poster 
29th International Symposium on High Performance Liquid Phase Separations and 
Related Techniques (Stockholm Sweden, June 2005). 
8. Farthing D., Xi L., Gehr L., Sica D., Larus T., and Karnes H.T.  HPLC determination 
of a potential biomarker of initial cardiac ischemia using isolated mouse hearts.  J of 
Biomarkers (2006) 11(5):449-459. 
9. Callicutt C.H., Cox R.H., Farthing D., Hsu F.S., Johnson L., Laffoon S.W., Lee P., 
Kinser R.D., Podraza K.F., Sanders E.B. and Seeman J.I.  The ability of the FTC 
method to quantify nicotine as a function of ammonia in mainstream smoke.  
Contributions to Tobacco Research, (2006) 22(2):71-78. 
10. Farthing D., Sica D., Fakhry I., Larus T., Ghosh S., Farthing C., Vranian M., and Gehr 
T.  Simple HPLC-UV method for determination of iohexol, iothalamte, p-
aminohippuric acid and n-acetyl-p-aminohippuric acid in human plasma and urine with 
ERPF, GFR and ERPF/GFR ratio determination using colorimetric analysis.  Poster 
Pittcon (Orlando Fl, 2-05). 
11. Farthing D., Sica D., Fakhry I., Larus T., Ghosh S., Farthing C., Vranian M., and Gehr 
T..  Simple HPLC-UV method for determination of iohexol, iothalamte, p-
aminohippuric acid and n-acetyl-p-aminohippuric acid in human plasma and urine with 
ERPF, GFR and ERPF/GFR ratio determination using colorimetric analysis.  J of 
Chrom B (2005) 826:267-272. 
12. Meruva N.K., Penn J.M., and Farthing D.  Rapid identification of microbial VOCs 
from tobacco molds using closed-loop stripping and GC/TOF-MS, J of Indus Micro & 
Biotech (2004) 31:482-488. 
13. Farthing D., Larus T., Fakhry I., Gehr T., Prats J., and Sica D.  Liquid chromatography 
method for determination of bivalirudin in human plasma and urine using automated 
ortho-phthalaldehyde derivatization and fluorescence detection, J of Chrom B (2004) 
802:355-359. 
14. Farthing D., Sica D., Abernathy C., Fakhry I., Roberts J.D., Abraham D.J., and 
Swerdlow P.  High-performance liquid chromtographic method for determination of 
vanillin and vanillic acid in human plasma, red blood cells and urine.  J of Chrom B 
(1999) 726:303-307. 
15. Farthing D., Fakhry I., Ripley E.B.D., and Sica D.  Simple method for determination of 
hydrochlorothiazide in human urine by high performance liquid chromatography 
utilizing narrowbore chromatography.  J of Pharm and Biomedical Analysis (1998) 
17:1455-1459. 
16. Farthing D., Sica D., Fakhry I., Pedro A., Gehr T.W.B.  Simple high-performance 
liquid chromatographic method for determination of losartan and E-3174 metabolite in 
human plasma, urine and dialysate.  J of Chrom B (1997) 704:374-378. 
17. Farthing D., Gehr L., Berger B., Fakhry I., and Sica D.  Simple method for 
simultaneous determination of halothane, enflurance, and isoflurane in krebs solution 
using capillary gas chromatography.  Biomedical Chrom (1997) 2:29-32. 
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18. Farthing D., Brouwer K.L.R., Fakhry I., and Sica D.  Solid-phase extraction and 
determination of ranitidine in human plasma by a high-performance liquid 
chromatographic method utilizing midbore chromatography.  J of Chrom B (1997) 
688:350-353. 
19. Farthing D., Sica D., Fakhry I., Walters D.L., Cefali E.A., and Allan G.  Determination 
of flutamide and hydroxyflutamide in dog plasma by a sensitive high performance 
liquid chromatography method utilizing mid-bore chromatography.  Biomed Chrom 
(1994) 8:251-254. 
20. Farthing D., Sica D.A., Fakhry I., and Gehr T.W.B.  Novel high-performance liquid 
chromatographic method using solid-phase on-line elution for determination of 
metolazone in plasma and whole blood.  J of Chrom B (1994) 653:171-176. 
21. Farthing D., Fakhry I., Gehr T.W.B., and Sica D.A.  Quantitation of metolazone in 
urine by high-performance liquid chromatography with fluorescence detection.  J of 
Chrom Biomed Appl (1990) 534:228-232. 
22. Karnes H.T., Farthing D., and Besenfelder E.  Solid phase extraction with automated 
elution and HPLC of torsemide and metabolites from plasma.  J of Liquid Chrom 
(1989) 12(10):1809-1818. 
23. March C., Farthing D., Wells B., Besenfelder E., Karnes H.T.  Solid-phase extraction 
and liquid chromatography of torsemide and metabolites from plasma and urine.  J of 
Pharm Sci (1990) 79(5):453-457. 
24. Karnes H.T., Beightol L.A., Serafin R., and Farthing D.  Improved method for the 
determination of diazepam and n-desmethyldiazepam in plasma using capillary gas 
chromatography and nitrogen-phosphorus detection.  J of Chrom Biomed Appl (1988) 
424:398-402. 
25. Karnes H.T., Rajasekharaiah K., Small R.E., and Farthing D.  Automated solid phase 
extraction and HPLC analysis of ibuprofen in plasma.  J of Chrom (1988) 11(2):489-
499. 
26. Farthing D., Gehr T.W.B., Fakhry I., and Sica D.A.  A direct injection method for 
determining furosemide and metolazone in urine using HPLC and fluorescence 
detection.  LC/GC magazine (1988) 9(7):478-480. 
27. Karnes H.T., Opong-Mensah K., Farthing D., and Beightol L.A.  Automated solid-
phase extraction and HPLC determination of ranitidine from urine, plasma and 
peritoneal dialysate.  J of Chrom Biomed App (1987) 422:165-173. 
28. Karnes H.T., and Farthing D.  Improved method for the determination of oxazepam in 
plasma using capillary GC and nitrogen phosphorus detection.  LC/GC magazine 
(1987) 5(11):978-979. 
29. Karnes H.T., Beightol L.A., and Farthing D.  Benzyl alcohol interference from heparin 
lock flush solutions in a HPLC procedure for mezlocillin.  Therap Drug Monit (1987) 
9(4):456-460. 
 
Professional Training / Seminars 
ACS Courses – GLP; QA/QC for the Laboratory; Troubleshooting HPLC systems; 
Practical LC/MS, Analysis and Interpretation of MS. 
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Pittcon Courses – Computer and Equipment Validation; Fast GC; ISO Guidelines for 
Uncertainty Calculations; Online Chemical Searching; Sampling of Solids, Gases, and 
Liquids; Statistics Review; Headspace Theory and Practical; Sample Preparations; HPLC 
Method Development for LC/MS. 
ASMS Courses – LC/MS. 
Thermo Nicolet – FT-IR Operation and Interpretation; XRF Operation and Interpreation. 
ISSX – Toxicology. 
Gerstel – Headspace; Thermal Desorption; Twister. 
Agilent – LC/MS Lab on a Chip; 5973 Agilent MSD Troubleshooting; Macro 
Programming. 
PBA Courses – Pharmacokinetics for Chemist, Metabonomics: Principles and Practices. 
Biomarkers – Biomarker assay development and validation. 
 
Professional Memberships and Activities 
American Chemical Society – since 1996 
ACS Chemical Toxicology – since 1996 
Journal of Chromatography B – manuscript reviewer since 2000 
Chromatographia – manuscript reviewer since 2006 
Member of Philip Morris R&D Emergency Response Team (hazmat, fire, medical) – 
1999-2006 
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Dr. H. Thomas Karnes 
Professor and Director of Pharmaceutics and Bioanalytical Laboratories 
Medical College of VA, Richmond, VA 23298 (804-828-6095) 
 
Dr. Domenic Sica 
Professor of Internal Medicine, Division of Nephrology, 
Section Head of Clinical Pharmacology and Hypertension 
Medical College of VA, Richmond, VA 23298 (804-828-6553) 
 
